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The field of tissue engineering aims to develop viable substitutes with the ability to 
repair and regenerate the functions of damaged tissue. Common practices to supplement 
bone regeneration in larger defects include bone graft biomaterials such as autografts, 
allografts, xenografts, and synthetic biomaterials. Autologous bone grafting is the current 
gold-standard procedure used to replace missing or damaged bone. However, these grafts 
have disadvantages such as donor site morbidity, limited availability, and the need for a 
secondary surgery. The focus of this study is to tissue engineer a lyophilized gelatin 
composite sponge composed of hydroxyapatite (HA), chitin whiskers (CW), and 
preparations rich in growth factors (PRGF) to provide sufficient structural support to the 
defect site while enhancing the body’s own reparative capacity, ultimately eliminating the 
need for autologous tissue harvesting or repeat operations. 
xii 
 
The present study investigates several in vitro evaluations on multiple compositions 
of modified gelatin sponge scaffolds for use in bone graft applications. Gelatin sponges 
were fabricated via freeze-drying, enhanced with PRGF, HA, and/or CW, and cross-linked 
with 50 mM 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) either 
during or post gelation. Initial evaluation of all scaffold combinations indicated that 
scaffolds released contents up to 90 days, EDC cross-linking during gelation allowed for 
more protein release, and had the ability to swell. Since the incorporation of PRGF, HA, 
and CW increased cell infiltration, and production of cell-created mineral matrix over 90 
days in culture, these scaffolds were further characterized. Freeze-dried gelatin sponges 
enhanced with PRGF, HA, and CW and cross-linked during gelation with EDC (PHCE) 
were mineralized (M) in 5x revised simulated body fluid (r-SBF) for 1 hour to create a 
bone-like mineral surface. Gelatin EDC scaffold controls (GE), GE-M, PHCE, and PHCE-
M scaffolds were characterized for their ability to swell, mineralizing potential, surface 
morphology, growth factor incorporation and release, uniaxial compression properties, and 
cell attachment, proliferation, infiltration, and protein/cytokine secretion.. After 
mineralization, scanning electron microscopy showed sparse clusters of mineral deposition 
for GE-M scaffolds while PHCE-M scaffolds exhibited a more uniform mineral 
deposition. Both GE and PHCE scaffolds were porous structures that swelled up to 50% of 
their original volume upon hydration. Over 21 days incubation, PHCE-M scaffolds 
cumulatively released about 30% of their original protein content, significantly more than 
all other scaffolds. Multiplex Luminex assays confirmed the successful incorporation of 
PRGF growth factors within PRGF sponges. For acellular uniaxial compression testing, 
xiii 
 
PHCE-M scaffolds reported lower Young’s modulus values (1.3 - 1.6 MPa) when 
compared to GE and GE-M scaffolds (1.6 – 3.2 MPa). These low modulus values were 
comparable to values of tissue found in early stages of bone healing. DAPI (4',6-
diamidino-2-phenylindole) staining and imaging showed an increase in initial cell 
attachment and infiltration of PHCE and PHCE-M scaffolds on day 1. GE-M scaffolds also 
appeared to attach more cells than the GE control. MTS cell proliferation assay results 
indicated that on days 4 and 7, PHCE scaffolds increased cell proliferation (compared to 
GE controls). MTS also illustrated that the addition of a mineral coating increases and 
decreases cell proliferation on GE-M and PHCE-M scaffolds, respectively. Multiplexer 
analysis of MG-63 protein/cytokine secretion suggests that cells are responding in a bone 
regenerative fashion on all scaffolds, as evidence of osteocalcin secretion. Little to no 
secretion of osteopontin, IL-1β, and TNF-α demonstrates that scaffolds are not influencing 
cells to secrete factors associated with bone resorption. The compressive mechanical 
properties of cellularized scaffolds did not differ much from acellular scaffolds. The 
collective results indicated increased cellular attachment, infiltration, and bone 
regenerative protein/cytokine secretion by cells on GE-M scaffolds, which support the 
addition of a bone-like mineral surface on GE scaffolds. Cellularized PHCE and PHCE-M 
scaffolds report similar advantages as well as Young’s modulus values in the range of 
native tissues present in the early stages of bone healing. The results of this study propose 
that the developed PHCE and PHCE-M scaffolds exhibit good cellular responses and 
mechanical properties for use in early bone healing applications. 
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1. ALTERNATIVE BONE GRAFTS – A CLINICAL NEED 
 
1.1. INTRODUCTION  
Healthy bone has the unique ability to spontaneously regenerate. However, bone 
injuries, particularly large bone defects/injuries, lack the ability to heal and have a severely 
limited reparative capacity ultimately requiring surgical intervention and replacement. 
Autologous bone grafting is the current gold-standard procedure used to replace missing or 
damaged bone and has been used for the regeneration of bone for multiple applications: 
dental implants (restore area of a missing tooth), spinal fusion, and repairing broken bones 
(that have bone loss or have not yet healed). Currently, there are more than 500,000 bone 
grafting surgeries performed in the United States each year, averaging between $33,860 to 
$37,227 per procedure, not including other expenses such as surgeon/anesthesiologist fees 
and hospital/medication charges [1, 2].  Although autologous bone grafting produces 
satisfactory results, these grafts carry the risk of donor site morbidity as well as limited 
availability. Other grafting options such as synthetic materials (metals and ceramics) elicit 
a foreign body response and are not biodegradable. The increasing number of bone grafts 
performed in the U.S. annually, combined with the drawbacks of autografts, has created a 
shortage of cadaver allografts and a need to increase musculoskeletal tissue donation. As a 
result, there has been an increase in corporate interest in regards to developing alternative 
bone grafting substitutes which include (but are not limited to) the use of natural, synthetic, 
human, and animal-derived biomaterials. The sales of bone grafts and bone-graft 
substitutes in the US have increased from 0.3 to 1.5 billion dollars from 1999 – 2009 with 
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increased spending on bone substitutes, platelet concentrators, bone morphogenetic 
proteins, and more [1]. This dissertation will particularly focus on tissue engineering a 
lyophilized (or freeze-dried) gelatin sponge enhanced with concentrated platelet-derived 
growth factors and bone extracellular matrix (ECM) factors which may provide sufficient 
structural support to the defect site while enhancing the body’s own reparative capacity, 
ultimately eliminating the need for autologous tissue harvesting or repeat operations. 
 
1.2. CURRENT TREATMENT OPTIONS FOR BONE GRAFTS 
 Common practices to supplement bone regeneration in larger defects include bone 
graft biomaterials such as autograft (patient’s own bone), allograft (human cadaver bone), 
xenograft (animal bone), and synthetic biomaterials (i.e. ceramics, cements, glasses, 
metals, polymers, and composites) [2-6]. The most common hard tissue graft is an 
autograft, whereby bone is taken from the patient’s own body and reimplanted into the 
defect site. Autologous bone grafts harvested from patient donor sites are osteoconductive 
(provide a scaffold where bone cells can proliferate), osteoinductive (induce proliferation 
of undifferentiated cells and their differentiation into osteoblasts), and osteogenic (provide 
a reservoir of skeletal stem and progenitor cells that can form new bone) [3].  Autografts 
are the best material for bone repair because of their supreme histocompatibility without 
the risk of disease transfer [4].  However, their limited availability, additional invasive 
surgery, and significant donor site morbidity (as shown in Table 1.1) are all drawbacks 
which encourage the development of alternative bone substitutes [3, 5-10]. The most 
frequently used donor site for autologous bone grafts is cancellous iliac bone. Alternative 
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donor sites have been explored [11, 12],  however even these suffer the same drawbacks 
mentioned above.  
 
Table 1.1 – Reported complication rates of harvesting iliac crest bone for autografts [10]. 
Reprinted with permission from Springer. 
 
 
 
 Allografts are an option for bone grafting because they are harvested from cadaver 
donors which means they are readily available, can be prepared in various shapes/sizes and 
there is no need to compromise or sacrifice the patient’s own bone (no donor site morbidity 
or secondary surgery for harvesting). The main disadvantage of allografts is the potential 
for disease transfer. Although, the allograft providers do their best to inactivate viruses, 
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there is still the possibility that not all infectious contents (such as blood and cellular 
components) were sufficiently destroyed. Even if the processing and irradiation protocols 
are successful in removing any threats for disease transfer, it is still possible for these 
procedures to compromise the graft’s biomechanical and biochemical properties. The 
overall challenge with allografts is to prepare well cleaned, sterile, and free of virus 
implants, while maintaining the natural biologic and biomechanical properties of the tissue 
[1, 13].  
 Xenografts are grafts derived from another species other than the host. For humans, 
the most common xenografts are harvested from bovine bone [14]. Before implantation in 
humans, the organic components of the graft are completely removed (to ideally eliminate 
human rejection by the immune response) leaving only the inorganic portions which serve 
as the natural architecture matrix and a source of calcium [15]. The disadvantages of 
xenografts include potential disease transfer (similar to allografts), infection, and rejection 
by the host immune system [16]. 
The field of tissue engineering “aims to restore function to or replace damaged or 
diseased tissues through the application of engineering and biological principles” [17]. 
Given that each of the above mentioned grafts has their own distinct disadvantages, 
synthetic biomaterial scaffolds that are biocompatible, biodegradable, porous, bioactive, 
and mechanically stable have been the focus of research as alternative bone substitutes. 
The use of polymeric scaffolds and tissue engineering techniques can achieve bone repair 
while eliminating the need for autologous grafts. Most research has centered on developing 
some form of a mineralized biomimetic scaffold that is biocompatible, mechanically 
5 
 
stable, has a moderate degradation rate over several months, and is osteogenic. These 
biomimetic structures are typically composed of synthetic/natural polymers and some form 
of calcium phosphates (usually hydroxyapatite, HA). Although many of these structures 
contain the basic ECM components of bone, they lack enhancing osteogenic promoting 
proteins and true three-dimensionality. Chapter 2 will provide a review of alternative bone 
graft substitutes within the field of bone tissue engineering.  
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2. BACKGROUND INFORMATION 
 
 
2.1. BONE: STRUCTURE AND REMODELING  
       Bone is a natural composite of collagenous organic matrix reinforced by an 
inorganic mineral phase of HA whose structure is ultimately responsible for its functional 
properties. Other components of bone include calcium phosphates, water, proteins, etc. 
[18]. Natural bone is a complex and highly organized structure of parallel collagen 
nanofibrils, and carbonated apatite (HA nanocrystals) located within the fibrils and 
precipitated on their surface [18, 19]. These HA nanocrystals can be either platelet or 
spindle shaped and up to about 200 nm long which creates a large surface area for effective 
mineral exchange [20]. Type I collagen is the main organic component (composing about 
90%) of mineralized ECM and is the foundation upon which minerals are deposited. The 
ECM is the framework of each tissue which provides cues to promote cellular adhesion, 
migration, differentiation, and proliferation. Cells continually produce, secrete, and modify 
ECM components which attribute to a unique ECM structure and composition for each 
tissue. Ultimately, the biomechanical properties and biological function is attributed to this 
organic-inorganic nanocomposite bone ECM  [21].  
  Bone undergoes continuous yet subtle remodeling in order to achieve its function. 
The mineral components, such as calcium phosphates and HA are responsible for the 
hardness of bone. The toughness and visco-elasticity is attributed to the soft organic 
collagenous matrix [22]. At the cellular level, osteoblasts reside on the surfaces of bone 
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and are involved in the secretion of the osteoid (unmineralized organic matrix, mainly type 
I collagen) and subsequent formation, mineralization, and organization of bone ECM. 
Osteoblasts are also differentiated forms of progenitor cells (such as mesenchymal stem 
cells and stromal cells) that are recruited to the site in need of bone rebuilding [23]. Once 
mature osteoblasts rebuild the area in need they either undergo apoptosis or become 
integrated within the deposited matrix and become osteocytes which maintain the bone 
matrix by controlling the activity of osteoblasts and osteoclasts [24]. Osteoclasts are large, 
multinucleated phagocyte-like cells formed from the fusion of macrophages, which adhere 
to the bone surface and are responsible for mineral dissolution and the degradation of the 
organic phase (bone resorption) [21].  It is known that bone remodeling is regulated 
through an osteoblast-osteoclast coupling system in which both cell types signal each other 
to maintain the balance of bone rebuilding and resorption at the appropriate sites. Any 
imbalance of this system can cause diseases, such as osteoporosis. Specifically with bone 
rebuilding, little is known about the role of osteoclasts with regards to signaling osteoblast 
recruitment. It has been reported that platelet-derived growth factor bb (PDGF-bb) is one 
such factor released by osteoclasts that control osteoblast chemotaxis [25]. Within the last 
five years, a new bone cell type has been identified and studied. Like most tissues, the 
bone-lining tissues (endosteum and periosteum) contain a population of resident tissue 
macrophages (OsteoMacs) that are likely to play a role in bone healing and bone 
homeostasis (through regulating osteoblast function). OsteoMacs are a significant 
population within the osteal microenvironment (constitute about one sixth of the total cell 
population) confirming that cells other than osteoblasts reside on the bone surface [26-28].  
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Figure 2.1 – The basic multicellular unit of bone remodeling [21]. Reprinted with 
permission from Elsevier. 
 
Mineralization of bone first occurs at nucleation sites located within the hole zone 
regions of the organic matrix of bone (collagen fibrils). This region is a volume of space 
where mineral crystals (calcium phosphates, Ca-P) are deposited from the extracellular 
fluid. Since mineralization occurs in these hole zones, it suggests that the three-
dimensional geometry and the composition of the fibrils (mineral-filled collagen) are 
factors in mineralization; specifically suggesting that nucleation sites are located in the 
collagen fibrils within the hole zone regions [29]. This initial nucleation process occurs at 
independent sites within the collagen fibrils and does not damage or disrupt the matrix 
structure. After the initial nucleation, there is continuous formation of Ca-P crystals due to 
secondary nucleation of the already formed crystals. Also during this stage, primary 
nucleation sites within the hole zone which did mineralize are still able to nucleate Ca-P 
crystals. Throughout the mineralization process Ca-P undergo a phase transformation from 
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a solution (extracellular fluid) to a solid phase (Ca-P crystals). It is important to note that 
the increase in mineralization is due to the increase in the number of crystals rather than 
the increase in the size of the crystals already formed [29]. Mineralization of a polymer 
scaffold occurs in the same manner as described above for native bone. Mineral nucleation 
occurs first on the polymer surface  and then mineral crystals multiply on the nucleated 
mineral [30].  This native mineralization process is the underlying principles behind 
biomimetic mineralization described later. 
 
2.2. NORMAL BONE HEALING 
The process in which normal bone healing occurs is divided into three main stages: 
inflammatory, repair, and remodeling. To initiate the inflammatory stage, a hematoma is 
developed at the injury site. This fibrin clot provides the framework for inflammatory cells 
(such as monocytes and macrophages) and fibroblasts to infiltrate the site of injury which 
results in granulation tissue formation, vascularization, and migration/differentiation of 
mesenchymal stem cells (MSCs) [31]. It is known that a variety of growth factors 
contribute to the migration and differentiation of MSCs into bone building cells 
(osteoblasts). These growth factors are supplied by multiple sources, including the various 
migrating cells and the platelets from the clot [23]. The repair stage begins within 1 to 2 
weeks by removing damaged cells and replacing the weak fibrin clot with a more 
mechanically stable structure (callus). During the repair stage, cartilage and collagen are 
formed and subsequently mineralized. Eventually the callus ossifies (endochondral 
ossification) and becomes woven bone (newly formed bone only present in early 
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development or during bone repair) [23, 31, 32]. In the remodeling stage, the bone is 
restored to its original shape, structure, and mechanical strength. Here, the woven bone is 
remodeled into lamellar bone via osteoclast and osteoblast coupling as previously 
described. A popular area of bone tissue engineering is the focus on the repair and 
remodeling stage, specifically the differentiation of MSCs into osteoblasts and the 
osteoblasts ability to attach and produce organic-inorganic matrix. 
 
 
Figure 2.2 - Fracture healing: inflammatory and repair stages. Although remodeling is a 
stage of fracture healing, it is also a process that is continuously occurring in the body at 
all times and therefore is not included in the immediate healing diagram above [32]. 
Reprinted with permission from Elsevier. 
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 Intuitively, as the stages of bone healing progress, the mechanical properties of the 
tissue increases. As displayed in Figure 2.3, Leong et al. reported the changes in 
mechanical properties of bone fracture calluses in rats, specifically recording the 
indentation modulus of granulation tissue (0.55 ± 0.04 MPa), cartilage (1.36 ± 0.078 MPa), 
newly formed woven bone (36.5 ± 5.84 MPa), and cortical bone (7.2 ± 0.61 GPa). 
Although this study reports the indentation modulus and not elastic modulus, the general 
relationship of mechanical properties of healing bone can be extracted. For rat femur 
fracture callus healing cortical bone was approximately 200x, 5,300x, and 13,000x higher 
modulus values than woven bone, cartilage, and granulation tissue, respectively. 
Fabrication of scaffolds for this dissertation will cater to the lower mechanical properties 
of the early stages of bone healing (granulation tissue and cartilage) rather than newly 
formed or mature bone since the goal is to create a scaffold that mimics early healing and 
promotes osteoblast matrix deposition. 
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Figure 2.3 - Measurement of indentation modulus of rat fracture calluses at progressive 
stages in bone healing [33]. Reprinted with permission from Oxford University Press. 
 
2.3. BONE TISSUE ENGINEERING 
 Tissue engineering focuses on developing viable substitutes that are able to repair 
and regenerate the functions of damaged tissue [34]. Specifically, bone tissue engineering 
requires a scaffold to temporarily support cell adhesion and direct their growth into bone 
tissue until the scaffold is completely replaced by the new tissue [35]. Cells respond to 
environmental cues such as composition, topographical structure, mechanical properties, 
and presence of biological factors. Therefore, within tissue engineering, cellular response 
and subsequent tissue growth are dependent on the characteristics of the scaffolding 
system. Since cellular growth depends on the characteristics of the scaffolding system, it is 
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important to fabricate scaffolds that mimic the structure and composition of natural bone 
ECM [36].  
Several scaffold fabrication techniques for tissue engineering applications have 
been developed using biodegradable synthetic and/or natural polymers with the potential to 
incorporate bioactive molecules. Some of these include freeze-drying [18], solvent 
casting/particulate leaching [30, 37], gas foaming/particulate leaching [5, 7, 9], 
plates/meshes [38], solvent casting/salt leaching [39], salt leaching/solid-liquid phase 
separation [40], and electrospinning [8, 21, 36, 41-47]. Important factors in the success of 
bone tissue engineering scaffolds include biocompatibility, degradability, porosity, 
osteoconductivity, and mechanical stability. Biocompatibility and degradability can be 
controlled by the polymer(s) used. Osteoconductivity and mechanical stability can 
potentially be enhanced by the growth of a bone-like mineral (BLM) on the scaffold 
surface prior to cell seeding [37]. Porosity can be controlled by altering parameters during 
different scaffold fabrication techniques. Porosity is an important design criterion for 
scaffolds, as a highly porous scaffold will allow for neovascularization throughout the 
construct [48]. It has been demonstrated that scaffolds with increased pore size enhance 
osteoblast proliferation and differentiation throughout the scaffold as a result of increased 
oxygen and nutrient transport, and neovascularization [49-51].  
  Polymers (both natural and synthetic) are a promising category of potential 
biomaterials used for bone tissue engineering [3]. Natural polymers attract special interest 
in tissue engineering since they have high mineralization potential, are highly bioactive, 
biocompatible, biodegradable, and natural substrates where cells can attach, proliferate, 
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and function [52]. One main criticism of natural polymers is that (when used alone) they 
lack mechanical integrity and are more quickly degraded. Synthetic polymers have been 
specifically fabricated for medical applications because they are versatile and free of 
potential contamination [53]. The advantage of using synthetic polymers for scaffolding is 
that they are more mechanically stable and able to undergo chemical modifications in order 
to improve cell adhesion, cell function, and mineralization. However, synthetic polymers 
generally lack bioactivity without these modifications which led to interest in developing 
composite scaffolds combining osteoconductive materials with polymer-based materials 
[3].  
There has also been widespread use of Ca-P (such as HA) for bone tissue 
engineering applications [5]. The major advantages of HA include (i) it is the major 
inorganic component of bone matrix, (ii) they have affinity to many adhesive proteins, and 
(iii) they are osteoconductive materials directly involved in bone cell differentiation and 
mineralization process [22, 46].  Even though inorganic HA materials have many 
advantages, they have limited use as tissue engineering scaffolds because they are brittle 
[42]. However, combining the bone-bioactivity of the inorganic materials with the 
structural integrity of the organic polymers introduces an organic-inorganic composite 
scaffold specifically tailored for bone tissue engineering. Composite organic-inorganic 
scaffolds have the potential to satisfy the complex scaffold designs criteria such as material 
composition, architecture, structural mechanics, surface properties, and degradation 
properties and products [22].In addition, calcium-based ceramics undergo a phase 
transformation and precipitate on the surfaces as Ca-P crystals. This sequence of events 
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leads to the formation of a carbonate-containing BLM layer on the surface which enhances 
osteoconductivity and is essential in creating a bond with the living host bone [54-56]. 
Collagen and HA are popular materials when investigating bone scaffolds since 
their composites mimic the ECM of natural bone [18, 57-60]. More recently, gelatin 
(denatured collagen) has been used as a replacement for collagen since it is less expensive, 
easier to obtain, and contains similar functional groups which enhance cellular response 
[61]. Gelatin also contains specific binding domains, such as the RGD sequence, which are 
related to cell attachment [62]. Freeze-dried gelatin sponges have many advantages 
because they can be designed to fit any size defect/injury site, have the ability to swell and 
fill a void space, degrade controllably in a range of rates (due to various cross-linking 
methods) to ensure drug release and mechanical stability, and can be easily modified by 
incorporating various osteoconductive/osteoinductive materials (i.e. minerals, growth 
factors, proteins, etc.). These porous scaffolds are fabricated without the use of harsh 
organic solvents which addresses one of the drawbacks of alternative scaffold fabrication 
methods. The addition of bioactive inorganic HA to freeze-dried gelatin sponges creates a 
bone-like ECM scaffold which allows a more controlled drug delivery system and 
increases cellular attachment, proliferation, alkaline phosphatase activity, and osteocalcin 
production [63-65]. HA also has the ability to bind to a variety of molecules, including 
proteins. As a result, scaffolds incorporated with HA provide a more favorable 
environment through increased adsorption of serum adhesion proteins such as fibronectin 
and vitronectin [66]. Enhanced cellular responses have also been observed with the 
addition of other minerals (β-tricalcium phosphate, dicalcium phosphate dihydrate), 
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polymers (gellan, poly-lactide-co-glycolide) and proteins (bone morphogenetic protein, 
Wnt1 inducible signaling pathway protein) in combination with HA [67-69]. 
Other additions such as chitin whiskers (CW, i.e. chitin nanocrystals) and platelet-
rich plasma (PRP) have been used to increase the mechanical integrity (CW), bioactivity 
(CW and PRP), and osteogenic potential of scaffolds (PRP) [70-72]. Chitin is the second 
most abundant biopolymer next to cellulose and possesses many favorable properties such 
as non-toxicity, high crystallinity, biocompatibility and biodegradability. Acid-treatment of 
chitin can dissolve regions of low lateral order, resulting in elongated rod-like 
nanocrystals, termed “whiskers”. CW are an emerging and novel nanofiller that have been 
shown to bring about reinforcing effects on both synthetic and natural polymeric 
structures. The biocompatibility and biodegradability also make it one of the most 
promising nanofillers. In recent years, experiments studying CW have increased due to its 
availability, nontoxicity, and ability to mechanically reinforce polymer nanocomposites 
and enhance cell proliferation [70, 73-77].   
Platelet-rich plasma (PRP) is a simple and cost-effective method for collecting and 
concentrating autologous platelets for the purpose of activating and releasing their growth 
factor-rich alpha and dense granules. Upon collecting PRP, platelet-poor plasma (PPP) can 
also be obtained simultaneously. PPP contains little to no amounts of growth factors and 
high concentrations of fibrinogen. Results of numerous studies have demonstrated the 
versatility and effectiveness of PRP within wound healing, skin engineering, 
ligament/tendon engineering, cartilage repair, bone regeneration, and more [71, 78-83]. 
Particularly with bone regeneration, the addition of PRP has been reported to increase bone 
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density/mineralization, vascularization, and osteogenesis [71, 72, 84-86]. Preparation rich 
in growth factors (PRGF, a bioactive lyophilized version of PRP) contains high 
concentrations of growth factors such as platelet-derived growth factor (PDGF), 
transforming growth factor-β (TGF-β), insulin-like growth factor-1 (IGF-1), vascular 
endothelial growth factor (VEGF), epidermal growth factor (EGF), fibroblast growth factor 
(FGF), hepatocyte growth factor (HGF), and more [87-89]. PRGF also contains cell 
adhesive proteins such as fibronectin and vitronectin. Many of these factors are known for 
their angiogenic potential, however, their ability to enhance bone repair has also been 
studied. In relation to bone remodeling, these growth factors and proteins elicit a favorable 
cellular response which supports the incorporation of PRGF within scaffolds intended for 
bone tissue engineering [90-98]. The bone remodeling functions for some of these 
molecules are summarized in Table 2.1. PRGF can be easily incorporated into scaffolds at 
desired concentrations which ultimately allow consistent reproducible bioactive scaffolds. 
The incorporation of PRGF within gelatin sponges, the general combination of CW and 
PRGF, and the combination of PRGF with HA and/or CW in gelatin sponges are all areas 
that have yet to be explored. 
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Table 2.1 - Role of PRGF components in bone remodeling [87-94, 97-104]. 
 
 
Function 
PDGF 
MSC and progenitor cell recruitment, proliferation, 
migration and differentiation into osteoblasts 
TGF-β 
MSC differentiation, increased production of collagen 
and mineral matrix 
IGF-1 Osteoblast proliferation and differentiation 
VEGF Angiogenesis, endochondral ossification 
HGF 
Angiogenesis, osteoblast proliferation, increases 
osteoblast BMP-2 production 
EGF MSC migration and osteoblast differentiation 
FGF 
Angiogenesis, osteoprogenitor cell proliferation, 
differentiation, and expression of osteogenic markers 
and mineralization 
Fibronectin, 
Vitronectin 
Enhance formation of focal adhesions by osteoblasts, 
osteoblast migration 
 
Several cell types can be used for in vitro evaluation of bone tissue engineering. 
Some include undifferentiated osteoprogenitor cells (mesenchymal stem cells, stromal 
cells, and periosteal cells) and already differentiated osteoblasts. For this dissertation, MG-
63 cells were used to evaluate in vitro cellular response. MG-63 cells are human 
osteoblast-like cells derived from an osteosarcoma. These cells behave similar to 
osteoblasts with their attachment, migration, proliferation, and organic-inorganic matrix 
production. MG-63 cells are commonly used for evaluation of biocompatibility and 
cellular response to bone regenerative environmental cues, such as scaffolds [65, 67, 105-
109]. 
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2.4. BIOMIMETIC MINERALIZATION 
As previously mentioned, a BLM layer formed on the surface of biomaterials is an 
essential requirement for the material to bond to the living bone and enhance 
osteoconductivity. In 1990, Kokubo et al. developed an acellular solution, simulated body 
fluid (SBF), with ionic concentrations approximately equal to those of human blood 
plasma [110]. The most commonly used SBF is conventional (c-SBF). Oyane et al. revised 
the c-SBF and prepared new SBFs that were closer to the ionic concentration of blood 
plasma.  The SBFs developed were revised (r-SBF), ionic (i-SBF), and modified (m-SBF) 
[111]. Of these, r-SBF has the overall closest ionic concentrations to that of total blood 
plasma (Table 2.2). 
 
Table 2.2 - Ionic concentrations of blood plasma [112]. Reprinted with permission from 
John Wiley and Sons. 
 
 
 
SBF is used to induce mineral nucleation, creating a BLM layer on the surface of 
materials [110]. This technique can be used for complex porous scaffolds since the apatite 
crystals are generated from an aqueous solution. Immersion of scaffolds in SBF is an easy 
task and does not require any special equipment. It has been found that the BLM 
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(carbonated HA) layer generated resembles natural bone mineral in its nano-crystal size 
and low crystallinity [40].  SBF has been widely used for biomimetic BLM coating on 
bioinert materials to directly mimic the process of mineralization in native bone and to 
predict the in vivo bioactivity of the material [9, 30, 37, 38, 41, 43, 45, 113]. It has been 
found that if a material is able to form a BLM layer in short periods when immersed in 
SBF, then it will bond to living bone in short periods [114].     
The overall focus of this study was to characterize the first attempts of a tissue 
engineered freeze-dried gelatin composite sponge enhanced with PRGF, HA, and CW to 
provide sufficient structural support to the defect site while enhancing the body’s own 
reparative capacity, ultimately eliminating the need for autologous tissue harvesting or 
repeat operations. Composite gelatin sponges were further modified via mineralization and 
characterized to understand scaffold release, cell response, and mechanical properties. The 
central hypothesis of this study is that a biodegradable lyophilized gelatin composite 
sponge will serve as a bioactive structure to facilitate osteoblast attachment, migration, and 
matrix secretion while exhibiting controlled release and stable mechanical properties in the 
range of tissues present in early bone healing.  
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3.1. ABSTRACT 
 The purpose of this study was to perform a number of preliminary in vitro 
evaluations on an array of modified gelatin gel sponge scaffolds for use in a bone graft 
application. The gelatin gels were modified through the addition of a number of 
components which each possess unique properties conducive to the creation and 
regeneration of bone: a PRGF, HA, and CW. PRP therapy is an emerging practice that has 
proven effective in a number of clinical applications, including enhancing bone repair 
through improved deposition of new bony matrix and angiogenesis. As such, the inclusion 
of PRGF in our gelatin scaffolds was intended to significantly enhance scaffold bioactivity, 
while the addition of HA and CW were anticipated to increase scaffold strength. 
Additionally, the gelatin sponges, which readily dissolve in aqueous solutions, were 
subjected to 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) cross-
linking either during or post gelation to control their rate of degradation. Scaffolds were 
evaluated in vitro with respect to compressive strength, change in mass, protein release, 
and MG-63 cellular interaction, with results demonstrating the potential of the gelatin 
sponge scaffold for use in the regeneration of bone. 
 
3.2.  INTRODUCTION  
As previously mentioned, healthy bone has the unique ability to spontaneously 
regenerate. However, if the diseased or damaged area exceeds a certain size, bone grafting 
is needed to regenerate the tissue [115]. Common practices to supplement bone 
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regeneration in larger defects include bone graft biomaterials such as autografts, allografts, 
xenografts, and synthetic biomaterials (i.e. ceramics, cements, glasses, metals, polymers, 
and composites) [3, 116-119]. Since each of the above mentioned grafts have their own 
distinct disadvantages, synthetic biomaterial scaffolds that are biocompatible, 
biodegradable, porous, bioactive, and mechanically stable have been the focus of research 
as alternative bone substitutes.  
 The present study aimed to evaluate the release kinetics, difference in mass, 
mechanical properties, and cellular responses of multiple combinations of composite 
freeze-dried gelatin sponges. PRGF, CW, and/or HA were incorporated into the gelatin 
sponges and cross-linked during gelation or after lyophilization to increase the scaffolds’ 
overall compatibility as a bone tissue engineering substitute. The goal of this study is to 
create a scaffold that mimics the microenvironment of early bone healing. In turn, this will 
foster a hospitable environment for osteoblast attachment, migration, and secretion of bone 
matrix, which will lead to woven bone formation and remodeling. 
 
3.3. MATERIALS AND METHODS 
3.3.1. Fabrication of gelatin composite sponges 
All scaffolds were fabricated with a base solution of 30 mg/ml gelatin (Type B 
from Bovine skin, Sigma) in deionized (DI) water. For composite scaffolds, a total amount 
of 10 mg/ml of PRGF, HA, and/or CW were weighed, added to the 30 mg/mL gelatin 
solution, then sonicated if necessary (Table 3.1). Materials included HA nanopowder 
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(particle size < 200 nm (BET), Sigma-Aldrich), CW (prepared by following a published 
protocol [74]),  PRGF (created using published protocol [88]), and1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride  (EDC, Thermo Scientific). To create 
PRGF, fresh human whole blood from 3 donors was purchased, combined, and centrifuged 
(SmartPReP
®
 2) to create PRP. PRP then underwent a freeze (-70°C) – thaw (37°C) – 
freeze (-70°C) cycle to ensure platelet lysis and activation. Frozen PRP was then 
lyophilized to obtain a dry PRGF powder to be weighed and incorporated within the 
gelatin solution [88]. 
4 mL of the prepared gelatin or gelatin composite solution was pipetted into a 35 x 
10 mm Petri dish, refrigerated at 4°C overnight to gel, and then slowly frozen at -15°C 
overnight, -20°C for 4 hours, and -70°C for 4 hours. Frozen gel composites were 
lyophilized for 24 hours then cross-linked for 18 hours at room temperature in 50 mM 
EDC in ethanol [120-123]. To analyze the effect of an alternative cross-linking method,  
another set of solutions were made and 50 mM EDC was added directly to the composite 
solution before gelation. This process allowed for simultaneous gelation and cross-linking 
(scaffolds denoted as +EDC). After gelation, scaffolds were frozen and lyophilized as 
previously described.  Using a Miltex biopsy punch, 6 mm discs were punched and used 
for all experiments. 
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Table 3.1 - Scaffold components and fabrication concentrations. 
 
 
amount (mg/mL) added to gelatin 
solution sonicated 
+HA 10 yes 
+CW 10 yes 
+HA+CW 5 (HA) and 5 (CW) yes 
+PRGF 10 no 
+PRGF+HA 5 (PRGF) and 5 (HA) yes (HA) then PRGF added 
+PRGF+CW 5 (PRGF) and 5 (CW) yes (CW) then PRGF added 
+PRGF+HA+CW 3.33 (PRGF), 3.33 (HA), and 3.33 (CW) 
yes (HA+CW) then PRGF 
added 
 
 
3.3.2. Mass loss 
Two 6 mm scaffold punches were weighed as a unit for initial dry mass. Scaffolds 
were then disinfected (30 minutes ethanol followed by three 10 minute washes of 1x 
Phosphate Buffered Saline, PBS – Quality Biological, Inc., pH 7.4) and transferred to a 48-
well plate (two discs per well, n=3). 500 µL of Dulbecco’s modified Eagle’s medium 
(DMEM, HyClone) high glucose containing 10% fetal bovine serum (FBS, Atlanta 
Biologicals) and 1% penicillin/streptomycin (HyClone) was added to each well. The two 
scaffolds per well were incubated in media at 37°C and 5% CO2 with media changes every 
7 days. Scaffolds were removed and weighed as a unit every 7 days up to 90 days. 
Hydrated scaffolds were massed and compared to original dry weights as a percentage to 
determine percent increase in scaffold mass. Scaffolds were air-dried post 90 day culture 
and compared to original dry weights to determine overall mass loss.  
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3.3.3. Protein release 
To determine total protein content of each 6 mm scaffold disc, triplicates of one 
non cross-linked 6 mm discs of each scaffold type was immersed in 500 µL of 1x PBS. 
Uncross-linked scaffolds completely degraded within minutes at room temperature. Since 
scaffolds are primarily comprised of gelatin, the released components are detectable using 
a general protein assay. Protein was quantified using a Pierce BCA Protein Assay (Thermo 
Scientific) with 8 serial dilutions of bovine serum albumin as standards (from 2 to 0 
mg/mL). Briefly, 25 µL of PBS containing the degraded scaffold contents was added to 
200 µL of working reagent in a 96-well plate. The well plate was then incubated at 37°C 
for 30 minutes, cooled to room temperature, and absorbance measured at 562 nm using a 
SpectraMax Plus 384 Microplate Spectrophotometer (Molecular Devices).  
Scaffold release kinetics was studied by quantifying protein release from each 
scaffold over a period of 90 days. Triplicates of one 6 mm disc of each cross-linked 
scaffold type were incubated in 500 µL of 1x PBS at 37°C with PBS replaced every 3 
days. After 1, 4, 7, 10, 14, 21, 28, 56, and 90 days the PBS containing released scaffold 
contents in each well was analyzed for protein content using the Pierce BCA Protein Assay 
described above.  
3.3.4.  Cell attachment, migration and matrix production 
Triplicates of 6 mm discs of each scaffold composition were seeded with 50,000 
osteoblast-like cells (MG-63 cells from a human osteosarcoma) and incubated at 37°C and 
5% CO2 in DMEM high glucose media containing 10% FBS and 1% 
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penicillin/streptomycin with media changes every three days. After 1, 28, and 90 days, 
scaffolds were fixed in 10% Buffered Formalin Acetate (Fisher Scientific) and stored at 
4°C until preparation for scanning electron microscopy (SEM) and fluorescent staining. 
For uniaxial compression testing, scaffolds were tested directly after being removed from 
the incubator. 
 
Scanning electron microscopy 
 Scaffolds were removed from formalin, briefly rinsed in PBS and water, and then 
subjected to ethanol dehydration (10 minute soaks in 30, 50, 70, 90, and 100 % ethanol, 
subsequently). Samples were air dried overnight, mounted on aluminum stubs, sputter 
coated in gold for 70 seconds, and examined using a JEOL JSM-5610LV scanning electron 
microscope. 
 
 DAPI staining 
Scaffolds were removed from formalin, immersed in a 30% sucrose solution in DI 
water for 48 hours at 4°C to ensure displacement of all air bubbles, suspended in premium 
frozen section compound (VWR), and frozen at -70°C overnight. 60 µm slices were 
cryosectioned using a Cryostat (Thermo) and transferred to microscope slides. 
Cryosectioned samples were then stained with 4’-6-diamidino-2-phenylindole (DAPI) 
stain for 5 minutes and imaged using a UV fluorescent microscope to display the location 
of cell nuclei.  
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Alizarin Red S staining 
Alizarin Red S (ARS) is a dye that selectively binds to calcium salts. ARS staining 
was used to quantify scaffold mineral content by modifying a published protocol [112]. 
ARS was performed on the 6 mm scaffold punches after 1, 28, and 90 days incubation in 
media with and without cells. After incubation scaffolds were stained with 40 mM Alizarin 
Red (Sigma-Aldrich) for 30 minutes then washed with DI water to remove any unbound 
stain. Scaffolds were then transferred to a 2 mL microcentrifuge tube containing 1.5 mL of 
50% acetic acid to destain for 1 hour at room temperature. 500 µL of the solubilized stain 
was added to 600 µL of 1 M NaOH to adjust the pH to 4.1. 200 µL of this solution was 
pipetted into a 96-well plate and absorbance read at 550 nm using a SpectraMax Plus 384 
Microplate Spectrophotometer. 
3.3.5. Uniaxial compression testing 
Uniaxial compression testing was performed on acellular and cellularized 6 mm 
scaffold discs after 1, 28, and 90 days incubation in media. Mechanical testing was 
conducted by attaching an indenter (cylindrical, 2 mm diameter, plane-ended, stainless 
steel) to a MTS Bionix 200 Mechanical Testing System instrument with a 100 N load cell 
(MTS Systems Corp., USA, Figure 3.1). Indentation was performed perpendicular to the 
scaffold surface at the center of each scaffold disc. The discs were placed on a flat metal 
surface and kept hydrated with PBS. The indenter was lowered to the surface of the 
scaffolds and the following parameters were used: test speed of 0.5 mm/min, data 
acquisition rate of 10 Hz, a preload of 0.015 N, and a max indenter displacement of 90% of 
29 
 
the scaffold thickness. Peak load was calculated by the MTS software TestWorks 4.0. 
Many scaffolds at later time points did not register a preload until later in the testing which 
resulted in the indenter moving through the entire scaffold until reaching the maximum 
load of 100 N when the intender contacted the metal plate. In these instances, the 
maximum peak load plateau, just before the maximum load was reached, was extracted 
from the graph and reported.  
 
 
Figure 3.1 - Compressive mechanical testing set up with indenter.  
 
3.3.6.  Statistical analysis 
Statistical analysis was performed using JMP IN 9 statistical software (SAS 
Institute) to determine significant differences. Analysis of the data was based on a Kruskal-
Wallis one-way analysis of variance on ranks and a Tukey-Kramer pairwise multiple 
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comparison procedure. The results are presented in mean ± standard deviation (SD). 
Unless otherwise specified all samples were run at a minimum of triplicate (n=3) to ensure 
statistical significance (p<0.05). 
3.4. RESULTS AND DISCUSSION 
3.4.1. Mass loss 
Figure 3.2 below shows the percent difference in mass between original dry 
scaffold weight, days 1, 28, 90, and dry post-culture scaffold weight. When comparing the 
two methods of cross-linking, scaffolds cross-linked post-fabrication absorbed more media 
and gained more mass (between 1500-2800 %) than scaffolds that were cross-linked 
during gelation (+EDC, between 500-1600 %). Upon comparing post cross-linked 
scaffolds at days 1, 28, and 90, the gelatin scaffolds showed significantly higher (p<0.05) 
mass increase than any other scaffold type. Also, CW and all scaffolds containing PRGF 
showed statistically significant (p<0.05) increases in mass at day 90 when compared to day 
1, suggesting that these scaffolds continuously absorbed media throughout the culture 
period. For +EDC scaffolds, most scaffold types reached their maximum weight after day 
1 and did not increase in mass over 90 days incubation. Only CW and PRGF+HA+CW 
scaffolds showed significant (p<0.05) mass increases. On days 1 and 28, HA scaffolds had 
significantly higher (p<0.05) percent differences in mass than all other scaffolds except for 
HA+CW and PRGF+HA+CW scaffolds, respectively. After 90 days, the percent difference 
in mass of HA scaffolds was only significantly higher than gelatin, PRGF, and PRGF+CW 
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scaffolds. Overall, the post cross-linked scaffolds swelled and absorbed more media than 
the +EDC scaffolds.    
 
 
 
Figure 3.2 - Percent difference in mass.  
 
 
Table 3.2 below compares the original dry pre-culture mass (Pre) to the dry, post 
90 day culture mass (Post) of each scaffold type for both cross-linking methods. All 
scaffolds that were cross-linked post-fabrication significantly increased in dry mass after 
culture. For +EDC scaffolds, all scaffolds containing HA showed significant increases in 
mass while PRGF scaffolds significantly decreased in dry mass. The reason for this 
increase in mass following a 90 day culture period is not completely understood, especially 
since each scaffold demonstrated protein release throughout its culture duration that would 
be indicative of an overall mass loss. It is hypothesized that the gelatin sponges absorbed 
FBS-resident proteins present in the complete media in which they were incubated, which, 
upon subsequent drying and removal of any liquid prior to the post-culture massing 
remained trapped within the scaffold’s structure. The swelling and media absorption seen 
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when dry scaffolds were introduced into culture media demonstrated that the gelatin 
scaffolds had a tremendous hygroscopic potential, thereby making it feasible that large 
amounts of FBS-resident proteins could be introduced and retained within the scaffold’s 
structure. Since the post cross-linked scaffolds absorbed more media than the +EDC 
scaffolds, the increase in mass for these scaffolds could be attributed to the higher 
absorption of media resulting in increased resident protein integration with the scaffolds. 
The post dry mass increase observed in +EDC scaffolds containing HA may be attributed 
to increased resident protein integration as well, considering that HA is a bioactive 
nanofiller with the capability of increasing binding sites for proteins, minerals, and cells. 
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Table 3.2 - Mass (mg) of dry scaffolds pre/post-incubation. * denotes post-culture mass is 
statistically different (p<0.05) than pre-culture mass.  
 
   
+EDC 
 
Pre Post Pre Post 
Gelatin 7.97 ± 0.57 14.27 ± 1.51* 7.53 ± 1.40 6.20 ± 1.71 
+HA 12.17 ± 0.61 19.10 ± 0.78* 8.17 ± 0.67 11.00 ± 1.31* 
+CW 10.67 ± 0.98 17.13 ± 9.29* 11.23 ± 0.95 10.63 ± 1.45 
+HA+CW 11.20 ± 0.70 19.13 ± 8.39* 7.23 ± 0.29 7.93 ± 0.95 
+PRGF 10.83 ± 0.99 18.53 ± 1.60* 9.40 ± 0.53 7.13 ± 0.81* 
+PRGF+HA 11. 07 ± 0.45 17.43 ± 0.47* 8.13 ± 0.76 9.47 ± 0.21* 
+PRGF+CW 9.63 ± 1.01 16.10 ± 0.27* 8.33 ± 0.50 7.73 ± 0.31 
+PRGF+HA+CW 11.33 ± 0.65 18.23 ± 0.40* 8.10 ± 0.26 9.47 ± 0.25* 
 
 
3.4.2. Protein release 
Original total protein content of all scaffolds was between 1500 and 2100 µg. The 
+HA and +PRGF+HA scaffolds contained lower amounts of original protein when 
compared to other +PRGF scaffolds while all other scaffolds were not statistically different 
(p<0.05) from each other (Figure 3.3).  
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Figure 3.3 - Original protein content of scaffolds. * denotes statistical differences 
(p<0.05). The black and blue lines show statistical difference of +PRGF+HA and +HA, 
respectively. 
 
 
The protein release kinetics of different cross-linking methods and scaffold 
compositions are compared over a 90 day incubation period and shown in Figure 3.4 A and 
B. All +EDC scaffolds released higher amounts of protein after 1 day incubation than their 
post-gelation cross-linked counterparts. The protein released from each +EDC scaffold 
ranged between 40 and 185 µg while the post-gelation cross-linked scaffolds only released 
a maximum of 35 µg. All +EDC scaffolds followed the same trend of protein release; a 
high release on day 1, a steady decline throughout 14 days, a jump at day 21, then declined 
to little/no release after 90 days. Throughout 56 days, the +EDC gelatin and +HA scaffolds 
showed consistently higher and lower release, respectively. Post-gelation cross-linked 
scaffolds had more variety in trends, however, the overall protein release remained low in 
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comparison to the +EDC scaffolds.  Graphs C and D in Figure 3.4 show the cumulative 
protein released from scaffolds over 90 days. These graphs show the same trends as graphs 
A and B; however, it provides a better perspective on overall protein release.  
 
 
 
 
 
Figure 3.4 - (A & B) Protein release of scaffolds per time point. (C & D) cumulative 
protein release over 90 days.  
 
 
 Total protein released from each scaffold after 90 days (Figure 3.4 C and D) was 
compared to the original protein content of the scaffolds (Figure 3.3) to compute a 
percentage of total protein released for each scaffold type after 90 days incubation. Table 
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3.3 lists these percentages in descending order. The overall trend was that scaffolds cross-
linked during gelation (+EDC) released more protein over 90 days than post-gelation 
cross-linked scaffolds. These results indicate that the method of cross-linking has a 
significant impact on the release kinetics of the scaffolds. In this study, where EDC 
concentrations were identical between the two cross-linking methods (pre or post-gelation) 
and the only difference was when the cross-linker was applied, it was apparent that the pre-
gelation +EDC group were faster degrading than the post-gelation group. It is hypothesized 
that the post EDC scaffolds degrade slower as a result of their stronger surface cross-
linking since these scaffolds were submerged in an EDC solution. However, the +EDC 
scaffolds were allowed to cross-link during gelation most likely resulting in more uniform 
cross-linking throughout the interior of the scaffold. The lower amounts of cross-linking on 
the surface could make the scaffold susceptible to faster degradation. While a quick rate of 
degradation may not be ideal for a bone graft scaffolding material, it may be appropriate in 
an orthopedic drug delivery scenario where a more rapid, yet still controlled release of 
protein may be ideal. It should be noted that in this study, for the sake of simplicity, only a 
single concentration of EDC was utilized. The ability to increase or decrease the 
concentration of the EDC cross-linker allows users to truly tailor the rate of protein release 
from the scaffold by effectively increasing or decreasing the degree to which the scaffold is 
cross-linked.  
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Table 3.3 - Percent total protein released after 90 days.  
 
 
% 
Released 
+PRGF+EDC 27.79 
Gelatin+EDC 19.30 
+PRGF+HA+EDC 19.18 
+PRGF+HA+CW+EDC 16.75 
+PRGF+CW+EDC 15.62 
+HA+CW+EDC 13.94 
+CW+EDC 13.66 
+PRGF+HA 9.29 
+HA+EDC 8.61 
+PRGF 6.59 
+PRGF+HA+CW 5.32 
+HA 4.95 
Gelatin 3.43 
+PRGF+CW 2.98 
+HA+CW 1.68 
+CW 1.23 
 
 
3.4.3. Cell attachment, migration and matrix production  
Scanning electron microscopy  
Scaffold characterization, cell attachment, and matrix production was first analyzed 
via scanning electron microscopy (Figures 3.5 and 3.6). Visually, all the acellular scaffolds 
appeared similar in structure: a flaky surface with large pores. Differences were noticed 
when observing MG-63 cell attachment after day 1. For post-gelation cross-linked 
scaffolds, the addition of HA and any scaffold containing PRGF appeared to have more 
cells attached (small dots in image). The same trend was observed for +EDC scaffolds with 
the exception of +PRGF+HA+CW. As previously mentioned, PRGF contains cell adhesive 
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proteins such as fibronectin and vitronectin. In addition, HA has the ability to adsorb these 
and other cell adhesion proteins either from the serum once incubated or from the PRGF 
pre-scaffold fabrication. The presence (in PRGF and serum) and/or adsorption (of HA) of 
these cell adhesive proteins allow the scaffolds containing HA and/or PRGF to increase in 
bioactivity and ultimately attach more cells, compared to the gelatin controls. After 28 
days, little to no matrix was produced by the cells on the post-gelation cross-linked 
scaffolds, however, the +HA, +HA+CW, +PRGF, and +PRGF+HA+CW +EDC scaffolds 
showed mineral matrix production by the cells. After 90 days, cells on the post cross-
linked scaffolds appeared to produce a more collagen bundle-like morphology matrix 
rather than a bone-like mineral substance. Cells on +EDC scaffolds for 90 days appeared to 
have produced more mineral matrix on the surface when compared to post cross-linked 
scaffolds. By visual inspection of the SEM images, cells produced desired bone-like 
mineral formation on the +HA, +HA+CW, +PRGF, and +PRGF+HA+CW +EDC scaffolds 
suggesting these scaffolds to be conducive to bone formation. 
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Figure 3.5 - SEM of post cross-linked scaffolds seeded with MG-63 cells for 1, 28, and 90 
days. Magnification at 450x and scale bars at 50 µm. 
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Figure 3.6 - SEM of +EDC cross-linked scaffolds seeded with MG-63 cells for 1, 28, and 
90 days. Magnification at 450x and scale bars at 50 µm. 
41 
 
Alizarin Red S staining 
 Absorbance was measured to compare the relative mineral content of the cellular 
and acellular composite gelatin sponges incubated for 90 days (Figure 3.7). Each scaffold 
composition was compared to itself at each day to determine if the addition of MG-63 cells 
significantly increased or decreased (p<0.05) overall scaffold mineral content. Scaffolds 
were only compared to themselves and not to other compositions since the initial amount 
of mineral per scaffold varied (i.e. all scaffolds containing +HA had higher absorbance 
values than scaffolds without +HA). For post cross-linked scaffolds, gelatin, +CW, and 
+PRGF showed a significant decrease (p<0.05) in absorbance after 90 days with cells 
when compared to 90 days without cells. The only post cross-linked scaffold that had a 
significant increase (p<0.05) in mineral content as a result of cells was +PRGF +HA at day 
28. For +EDC scaffolds, the addition of cells resulted in significant decreases (p<0.05) in 
mineral content in gelatin (day 90), +PRGF (day 90), and +PRGF +CW (day 28 and 90) 
scaffolds. However, there were more +EDC scaffolds that recorded higher absorbance 
values as a result of the cells producing mineral matrix: +CW (day 28), +HA (day 28 and 
90), +PRGF +HA (day 28 and 90), and +PRGF +CW +HA (day 28).  
While the ARS results were not consistent for a specific group, the fact that a 
number of groups exhibited statistically significant increases in mineral matrix production 
was seen as a positive result indicative of the potential in vitro formation of new bone. The 
statistically significant decreases between day 90 acellular scaffolds and day 90 
cellularized scaffolds could be attributed to the previous mention of acellular scaffolds 
continuously absorbing media (and in conjunction, resident proteins and calcium ions 
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within the media) over 90 days. Alternatively, cells seeded on scaffolds remodel the 
constructs as the cells migrate, proliferate, and produce matrix. The ARS stain may have a 
higher affinity to these adherent resident proteins and calcium than a partially degraded 
scaffold covered with cells, resulting in a higher ARS absorbance for acellular scaffolds. It 
has been shown that Alizarin Red S has the ability to also bind to human serum albumin 
(HSA) [124]. HSA is the most abundant protein in whole blood; as such it is present in 
PRGF. In addition, bovine serum albumin is present in the cell culture media and can 
potentially have binding affinity to ARS. In either instance there may be confounding 
variables when using ARS on samples that have components of blood or that have been 
exposed to culture media. Overall, the very nature of the ARS procedure (multiple 
staining/de-staining and washing steps) makes it difficult to obtain truly accurate 
quantifications of mineral production of cells on scaffolds. However, for the preliminary 
nature of this study the ARS stain and its fairly positive results proved adequate in 
demonstrating the osteoinductive potential of the modified gelatin sponges tested here.  
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Figure 3.7 - ARS of acellular and cellular scaffolds over 90 days incubation. * denotes a 
statistical difference (p<0.05) between cells and no cells for a specific day and scaffold 
composition. # denotes a statistical difference (p<0.05) when comparing cross-linking 
methods of each condition. 
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 Statistical analysis was also performed between the two graphs to determine if 
there were any significant differences in absorbance for a given scaffold on a particular 
time point. A total of six post cross-linked scaffolds and five +EDC scaffolds showed 
significant increases in absorbance values when compared to their cross-linked 
counterparts (Table 3.4).  
 
Table 3.4 - Scaffolds with significant increases (p<0.05) in absorbance values when 
comparing cross-linking methods. 
 
 
post cross-
linked +EDC 
Day 1 cells +PRGF +HA    
Day 28 +PRGF +PRGF +CW 
  +PRGF +HA    
Day 28 
cells   +CW 
    +HA 
Day 90 +PRGF +PRGF +CW 
  +PRGF +HA  
+PRGF +HA 
+CW  
Day 90 
cells +PRGF   
 
 
DAPI staining 
 The SEM images provided an overview of how cells attached and produced matrix 
on the surface of gelatin composite sponges. Cell attachment and more importantly, 
infiltration into the scaffold, was analyzed via DAPI staining. Not all images are reported 
due to spatial constraints; however, the pure gelatin scaffolds (controls) are compared to 
three other scaffold compositions that facilitated a more pronounced infiltration of cells. In 
Figure 3.8, post cross-linked gelatin scaffolds are compared to +PRGF, +PRGF +HA, and 
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+PRGF +HA +CW. After day 1, cells attached along the surface of the pure gelatin 
scaffold while the other scaffolds promoted cell infiltration and attachment (as evidence of 
blue cell nuclei visible throughout the cross section of the scaffold).  With post cross-
linked scaffolds, it appears that the addition of PRGF enhanced the attachment and 
infiltration of cells when compared to the gelatin control. The milieu of growth factors and 
cytokines contained within PRGF (some listed in Table 3.1) are known to be highly 
chemotactic as well as have the ability to induce cellular attachment, proliferation, and 
migration in a number of cell types. While the presence and release of PRGF derived 
biomolecules was not specifically investigated in this study, it can be assumed that the 
growth factors and cytokines contained within the PRGF are being eluted from the 
scaffolds based upon previous studies conducted with the incorporation of PRGF into 
electrospun scaffolds [87, 125]. These results suggest that these molecules remain active 
post-scaffold fabrication and ultimately increase the bioactivity of the scaffolds. 
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Figure 3.8 - DAPI staining of post cross-linked scaffolds with MG-63 cells for 1, 28, and 
90 days. Images taken at 20x magnification. 
 
 
Figure 3.9 compares the gelatin +EDC control to +CW, +PRGF, and +PRGF +CW 
+EDC. A similar trend was noticed with the +EDC scaffolds in that cells attached mainly 
to the control gelatin scaffold surface while the other scaffold compositions showed 
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enhanced cell infiltration after day 1. However, it appears that more cells penetrated and 
attached to +EDC scaffolds when compared to post cross-linked scaffolds. By day 28 and 
90, it became increasingly difficult to distinguish fluoresced cell nuclei on any scaffolds, 
independent of cross-linking methods. There appeared to be an abundance of newly 
created cell matrix at days 28 and 90, especially with +EDC scaffolds. This newly 
deposited matrix may have interfered with the staining, which commonly produced a 
uniform fluoresced scaffold making it difficult to discern individual cell nuclei and analyze 
day 28 and 90 DAPI images. With +EDC scaffolds, the addition of CW and/or PRGF 
appeared to promote cell attachment and penetration when compared to the gelatin +EDC 
control.  
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Figure 3.9 - DAPI staining of +EDC cross-linked scaffolds with MG-63 cells for 1, 28, 
and 90 days. Images taken at 20x magnification. 
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3.4.4. Uniaxial compression testing 
 Peak load was recorded to determine the compressive strength of the cellular and 
acellular composite gelatin sponges incubated for 90 days (Figure 3.10). Each scaffold 
composition was compared to itself at each day to determine if the presence of cultured 
cells strengthened or weakened the scaffold over the duration of culture. Most of the post-
gelation cross-linked scaffolds did not record a significant difference (p<0.05) between 
cellularized and acellular scaffolds, meaning that the addition of cells did not significantly 
affect the scaffolds compressive strength positively or negatively. However, significant 
increases (p<0.05) in peak load as a result of culturing cells were observed for +PRGF 
+HA +CW (day 1 and 28), +CW (day 28), and +PRGF +CW (day 28) post-gelation cross-
linked scaffolds. Many of the scaffolds cross-linked during fabrication (+EDC) also did not 
record significant differences (p<0.05) between cells and no cells when comparing 
scaffolds to themselves at a specific day. Significant increases (p<0.05) in compressive 
strength were recorded for +HA (day 28) and +CW +HA (day 28) scaffolds suggesting the 
addition of cells improved scaffold strength.  
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Figure 3.10 - Peak load (N) of acellular and cellular scaffolds over 90 days incubation. 
*denotes a statistical difference (p<0.05) between cells and no cells for a specific day and 
scaffold composition. # denotes a statistical difference (p<0.05) when comparing cross-
linking methods of each condition. 
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 Upon comparing peak load between cross-linking methods, it was noticed that for 
the majority of the scaffolds, the method of cross-linking had no significant effect (p<0.05) 
on the compressive strength for a specific scaffold on a particular day. Cross-linking 
during scaffold fabrication (+EDC) significantly increased (p<0.05) the compressive 
strength of +HA (day 28 cells) and +CW +HA (day 28 cells) scaffolds. On the other hand, 
+EDC scaffolds showed significant decreases in peak load for +PRGF +HA (day 28 no 
cells), +PRGF +CW (day 28 cells), and +PRGF +HA +CW (day 1 cells) scaffolds. 
 While the nano-indentation for compressive mechanical properties produced 
satisfactory results, future experiments will use a platen system for testing. Although the 
nano indenter was within the appropriate size in diameter (2 mm) when compared to the 
sample diameter (6 mm), there still remains the possibility of local variations in material 
properties [126]. The platen system compresses the sample using two flat platens (larger 
that the sample size) instead of a smaller indenter to measure mechanical properties.  
3.5. CONCLUSION 
 In this study it was demonstrated that a lyophilized gelatin gel sponge, modified 
through the addition of PRGF, HA, and CW, demonstrated clear osteogenic potential when 
cultured with an MG-63 osteoblast-like cell line. These scaffolds, further modified through 
EDC cross-linking during gelation, were able to remain intact after 90 days in culture 
while exhibiting a controlled protein release. This tailorable rate of degradation is critical 
in a bone repair scaffold, where scaffold breakdown needs to match the ingrowth of new 
bony matrix to prevent catastrophic failure or the potential for micromotion or stress-
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shielding to occur. While this preliminary study failed to determine a clear optimal 
combination of gelatin and scaffold modifying agents (PRGF, HA, CW) to promote bone 
regeneration, it demonstrated that the use of a lyophilized gelatin gel sponge with the 
potential to absorb several times its weight in water was capable of eliciting cell infiltration 
into the structures as well as promoting the formation of cell-created mineral matrix. 
However, the +EDC scaffolds containing +PRGF+HA+CW performed well in the 
preliminary evaluations and need to be further investigated going forward. Further testing 
must be performed to more accurately determine the cellular interaction with these 
scaffolds in particular the cellular response inside the structures.  
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4. MINERALIZATION AND FURTHER CHARACTERIZATION OF 
LYOPHILIZED GELTIN SPONGES ENHANCED WITH PRGF, 
HA, AND CW   
 
4.1. ABSTRACT 
 The application of freeze-dried gelatin sponges as alternative bone grafting 
substitutes has many advantages which include ability to swell, high porosity, tailorable 
degradation, and versatile ability to incorporate one or multiple components (proteins, 
growth factors, inorganic nanofillers, etc.). The previous study demonstrated the enhanced 
protein release and cell attachment/infiltration in scaffolds cross-linked during gelation 
(+EDC) and in scaffolds incorporated with biological factors (HA, CW, and PRGF). The 
purpose of this study was to further characterize freeze-dried gelatin sponges enhanced 
with PRGF, HA, and CW and cross-linked during gelation (PHCE). Freeze-dried 
gelatin+EDC (GE) scaffolds were used as a control. Scaffolds were also mineralized (M) 
in 5x r-SBF to create a bone-like mineral surface. GE, GE-M, PHCE, and PHCE-M 
scaffolds were characterized for their ability to swell, mineralization (ARS), surface 
characteristics (SEM), protein release (BCA protein assay), release of PRGF, and uniaxial 
compression properties (using 2 platens to record modulus and peak load). A growth factor 
profile of PRGF was also obtained using a human angiogenesis kit and a multiplexer. 
Growth factors detected in PRGF included VEGF-A, HGF, EGF, FGF-2, VEGF-C, IL-8, 
and VEGF-D (listed in descending order of concentrations present). Both GE and PHCE 
scaffolds were porous structures that swelled up to 50% of their original volume upon 
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hydration. SEM showed sparse clusters of mineral deposition for GE-M scaffolds while 
PHCE-M scaffolds exhibited a more uniform mineral deposition throughout the surface. 
ARS was unable to detect any differences between mineralized and non-mineralized 
scaffolds, however it did show a significant increase in mineral content between GE and 
PHCE scaffolds which was expected since HA was incorporated within PHCE scaffolds 
and not present in GE scaffolds. Over 21 days, scaffolds released more of their contents 
during the first 7 days when compared to later time points. By day 21, PHCE-M scaffolds 
cumulatively released about 30% of its original protein content, significantly more than all 
other scaffolds. For uniaxial compression testing of hydrated sponges, PHCE-M scaffolds 
report lower Young’s modulus values (1.3 - 1.6 MPa) when compared to GE and GE-M 
scaffolds (1.6 – 3.2 MPa). These low modulus values are comparable to values of tissue 
found in early stages of bone healing. The results of the study demonstrate the enhanced 
performance of PHCE and PHCE-M scaffolds to serve as bone healing scaffolds. Their 
potential to release incorporated factors and comparable composition and mechanical 
properties to tissues developed in the early stages of bone healing make them suitable for 
further studies evaluating cellular responses.    
4.2. INTRODUCTION 
 There are several properties and characteristics to consider when fabricating an 
ideal scaffold intended for bone tissue engineering. These include: biocompatibility, 
degradability (as scaffold degrades, space is created for new bone), porosity (angiogenesis 
and migration/infiltration of cells to deposit bone within), mechanical integrity (ability to 
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maintain its structure and mimic mechanical properties found in bone healing 
microenvironment), osteoconductivity (ability to support bone growth), and 
osteoinductivity (ability to differentiate osteoprogenitor cells into osteoblasts). A 
lyophilized gelatin sponge cross-linked with EDC during gelation provides a 
biocompatible, porous, and degradable scaffold. The addition of PRGF contains many 
growth factors and cytokines which are known to enhance angiogenesis and osteogenesis 
(as previously described). The incorporation of HA and CW is also known to enhance 
osteoconductivity and mechanical integrity. The further acquisition of minerals to a 
scaffold surface via SBF treatment can further enhance osteoconductivity of scaffolds. The 
purpose of this study is to characterize acellular cross-linked lyophilized gelatin sponges 
enhanced with PRGF, HA, and CW (PHCE). The addition of a bone-like mineral surface 
from SBF treatment created mineralized (M) scaffolds which were also characterized and 
compared to their non-mineralized counterparts. A growth factor profile of uncross-linked 
PHC scaffolds and dilutions of PRGF, PRP, and PPP was obtained to identify key growth 
factors present at different stages. Gelatin controls (GE) were compared to GE-M, PHCE, 
and PHCE-M in regards to mineralization, protein release, growth factor incorporation, and 
mechanical properties to determine if these scaffolds appropriately meet the design 
characteristics of an ideal bone tissue engineering scaffold intended for early bone healing.  
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4.3.  MATERIALS AND METHODS  
4.3.1. Fabrication of gelatin composite sponges 
 Based on the results from Chapter 3, the PRGF+HA+CW+EDC scaffolds exhibited 
desirable characteristics of a potential bone tissue engineering scaffold and was further 
studied in this experiment. Gelatin+EDC scaffolds served as the control. Lyophilized 
gelatin+EDC (GE) and PRGF+HA+CW+EDC (PHCE) sponges were fabricated using the 
same method as described in Chapter 3, Section 3.3.1. Briefly, a 30 mg/mL gelatin solution 
in DI water was used as the base solution for creating gels. For GE scaffolds, 50 mM of 
EDC was added to 4 mL of the gelatin solution, briefly mixed, pipetted into a 35 x 10 mm 
Petri dish, and stored in a refrigerator at 4°C overnight to gel. For PHCE scaffolds, 3.33 
mg/mL of both HA and CW were added to 4mL of the gelatin solution then sonicated. 3.33 
mg/mL of PRGF was then added to the gelatin-HA-CW solution and allowed to 
completely dissolve (about 3 mins). 50 mM EDC was then added to the 4 mL gelatin-
PRGF-HA-CW solution, briefly mixed, transferred to a 35 x 10 mm Petri dish, and 
allowed to gel overnight at 4°C. After gelation of all solutions, gels were slowly frozen to  
-70°C and lyophilized to obtain the composite porous sponges. 6 mm discs were then 
punched and used for all studies.  
4.3.2. Swelling percent 
 To quantify the initial swelling capability of the GE and PHCE lyophilized 
sponges, measurements of the scaffold’s dimensions were recorded dry and after 1 day 
hydration in DMEM high glucose media containing 10% FBS and 1% 
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penicillin/streptomycin. Volume was calculated using the standard equation for the volume 
of a cylinder (π * radius2 * height). The formula (hydrated volume – dry volume) / (dry 
volume) was used to determine the swelling ratio of each scaffold. This ratio was then 
multiplied by 100 to calculate the percent increase in volume for each scaffold as a result 
of hydration (swelling percent). 
4.3.3. Scaffold mineralization 
The ionic concentrations of the commonly used SBF, conventional SBF (c-SBF), 
are not exactly equal to those of blood plasma. Oyane et al. made revisions to c-SBF and 
created three new SBFs (revised (r), ionic (i), and modified (m)) that have ionic 
concentrations equal to, or closer to, those of blood plasma (Table 2.2). The ionic 
concentrations of the r-, i-, and m-SBFs were formulated to equal those of total blood 
plasma, dissociated blood plasma, and total blood plasma (except for HCO3-), 
respectively. Of the compositions, r-SBF is the closest to the concentration of total blood 
plasma; in fact it is an exact match.  For this reason, a r-SBF solution was prepared by 
following the published protocol for 1x r-SBF and increasing each ion concentration by a 
factor of 5 [111]. A higher (5x) concentration of SBF was chosen in order to effectively 
mineralize the scaffolds with minimal incubation time.  
Triplicates of 6 mm (diameter) discs were punched from each of the composite 
gelatin sponges and separately incubated in 1 mL of 5x r-SBF for 1 hour at 37°C and 5% 
CO2 atmosphere. Preliminary studies mineralized scaffolds for 1, 6, and 12 hours and 
determined that 1 hour incubation in 5x r-SBF was sufficient to mineralize the scaffold. 
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Mineralization was performed under static conditions with the discs completely submerged 
in SBF. After 1 hour incubation, scaffolds were removed and rinsed with DI water to wash 
off any minerals that were not bound to the scaffold.  To visually inspect surface 
mineralization, one scaffold disc was dehydrated and used for SEM analysis. For mineral 
quantification, Alizarin Red S staining was used. GE and PHCE mineralized scaffolds are 
denoted as GE-M and PHCE-M, respectively.  
4.3.4. Scanning electron microscopy  
Scanning electron microscopy (SEM) was performed in order to evaluate the 
scaffold surface characteristics prior to and following mineralization. GE, GE-M, PHCE, 
and PHCE-M samples were disinfected (30 minutes ethanol followed by three washes of 
1x PBS) to simulate preparation for cell studies, air-dried, mounted on an aluminum stub, 
carbon coated, and examined using a Hitachi SU-70 scanning electron microscope 
(accelerating voltage at 20 kV).  
4.3.5. Alizarin Red S staining 
Alizarin Red S (ARS) staining was used to quantify scaffold mineral content by 
modifying a published protocol as previously described in Chapter 3, Section 3.4.4. [112]. 
ARS was performed on the 6 mm scaffold punches before and directly after mineralization, 
and after 21 days incubation in 1x PBS at 37°C and 5% CO2. At the desired time points, 
scaffolds were stained with 40 mM Alizarin Red for 30 minutes then washed with DI water 
to remove any unbound stain. Scaffolds were then transferred to a 2 mL microcentrifuge 
tube containing 1.5 mL of 50 % acetic acid to destain for 1 hour at room temperature. 500 
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µL of the solubilized stain was added to 600 µL of 1 M NaOH to adjust the pH to 4.1. 200 
µL of this solution was then pipetted into a 96-well plate and absorbance read at 550 nm 
using a SpectraMax Plus 384 Microplate Spectrophotometer. Absorbance values were 
compared to each other to determine any change in mineral content as a result of 
mineralization or degradation.  
4.3.6. Scaffold protein release 
Release of protein from the scaffolds was measured as one parameter to assess 
potential degradation. To determine total protein content of each 6 mm scaffold disc, 
triplicates of non cross-linked 6 mm punch of each scaffold type were immersed in 1 mL 
of 1x PBS. Non cross-linked scaffolds completely degraded within minutes at room 
temperature, however scaffolds were left overnight to ensure complete degradation. Since 
scaffolds are primarily comprised of gelatin, the degraded byproducts are detectable using 
a general protein assay. Protein was quantified using a Pierce BCA Protein Assay as 
previously described (in Chapter 3, Section 3.3.3.). Scaffold release kinetics were studied 
by quantifying protein release from each scaffold over a period of 21 days. Triplicates of 
one 6 mm disc of each cross-linked scaffold type were incubated in 1 mL of 1x PBS at 
37°C with PBS replaced on every analysis point. After 1, 4, 7, 14, and 21 days the PBS 
containing released scaffold contents in each well was analyzed for protein content using 
the Pierce BCA Protein Assay.  
60 
 
4.3.7. Growth factor analysis  
The same protein release model described in Section 4.3.6 was used to identify and 
quantify the PRGF growth factors incorporated and released from PRGF containing 
scaffolds. After 1, 4, 7, 14, and 21 days the 1 mL of 1x PBS containing released PHCE and 
PHCE-M scaffold contents in each well was analyzed for specific growth factor content. 
As a control of total growth factors present in each scaffold, triplicates of 6mm discs of 
uncross-linked gelatin+PRGF+HA+CW (PHC) scaffolds were completely degraded in 
1mL of 1x PBS by overnight incubation at 37°C.  Dilutions of pure PRGF (100, 50, 10, 1, 
and 0.1 mg/mL), PRP (1:10 and 1:20), and platelet-poor plasma (PPP, 1:10, 1:20) in DI 
water were also analyzed to obtain a profile of growth factors present in PRGF, PRP, and 
PPP alone. This detection and quantification was accomplished by using a Luminex 
MagPix multiplexer (fluorescent imager) with the MILLIPLEX® MAP human 
angiogenesis/growth factor magnetic bead panel 1. The Angiogenesis kit contained 
analytes specific to detecting epidermal growth factor (EGF), granulocyte colony-
stimulating factor (G-CSF), fibroblast growth factor-1 (FGF-1), FGF-2, interleukin 8 (IL-
8), hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGF-A), 
VEGF-C, and VEGF-D. The basic concept behind the Luminex technology is the use of 
internally color-coded microspheres which are each coated with a specific capture antibody 
(capable of capturing the analytes above). These microspheres are mixed with the released 
contents of PHCE and PHCE-M scaffolds where the specific capture antibody can capture 
the appropriate analyte. After this occurs, a biotinylated detection antibody is introduced 
followed by the addition and incubation of a reporter/detection molecule to complete the 
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reaction on the surface of each microsphere. Presence and quantification of analytes are 
detected based on fluorescent reported signals read by the Magpix system.   
4.3.8. Uniaxial compression testing 
Uniaxial compression testing was performed on acellular 6 mm scaffold discs after 1, 4, 
7, 14, and 21 days incubation in media. Mechanical testing was conducted by using 2 flat 
metal platens from tension grips (in place of the indenter described in Chapter 3) attached 
to a Bionix 200 Mechanical Testing System instrument with a 100 N load cell (MTS 
Systems Corp., USA). The platen system was used to increase accuracy of compressive 
mechanical testing by increasing the area of compression on the scaffold. The 2 platens 
spanned the entire 6 mm scaffold disc, while the indenter was only 2 mm in diameter. 
Platen compression was performed perpendicular to the scaffold surface without any 
circumferential constraints to allow for free lateral deformation (Figure 4.1). Scaffolds 
were removed from media, dabbed on a kimwipe to remove excess media/liquid, then 
placed on the flat metal surface (samples were still hydrated). The upper platen was 
lowered to the surface of the scaffolds and the following parameters were used: test speed 
of 0.5 mm/min, data acquisition rate of 10 Hz, and a preload of 0.01 N. Compression was 
continuous until the scaffold was completely flattened, the platens were compressing 
against each other, and terminated just before the system maxed out at 100 N. Peak load 
and Young’s modulus for compression were extracted and calculated using the graphical 
output from the MTS software TestWorks 4.0. Peak load was extracted from the largest 
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load value before the system began to max out. The compression modulus was calculated 
using the initial linear region of the stress-strain curve [127].  
 
 
Figure 4.1 - Compressive mechanical testing set up with scaffold between flat platens.  
 
4.3.9. Statistical analysis 
Statistical analysis was performed using JMP IN 9 statistical software (SAS Institute) to 
determine significant differences. Analysis of the data was based on a Kruskal-Wallis one-
way analysis of variance on ranks and a Tukey-Kramer pairwise multiple comparison 
procedure. The results are presented in mean ± standard deviation (SD). Samples were run 
at least in triplicates (n=3) to ensure statistical significance (p<0.05). 
 
 
63 
 
4.4. RESULTS AND DISCUSSION 
4.4.1. Swelling percent 
 In Chapter 3, it was discovered that these lyophilized gelatin composite sponges 
have the ability to absorb the solution they are hydrated in (media and 1x PBS) and 
significantly increase their mass. By calculating the swelling percent, we are able to further 
characterize the hygroscopic nature of these sponges and their ability to potentially fill a 
void space upon implantation. By calculating changes in volume, it was determined that 
both GE and PHCE lyophilized sponges swelled approximately 50% (Figure 4.2). There 
was no statistical difference (p < 0.05) between the swelling of GE and PHCE scaffolds 
suggesting that the added components of PRGF, HA, and CW do not enhance nor hinder 
the swelling ability of the scaffold. The result of no statistical differences in swelling could 
be attributed to the fact that the 3.33 mg/mL of each PRGF, HA, and CW added to the 30 
mg/mL gelatin solution was too low to overcome the natural sweling properties of the 
gelatin sponge. It would be interesting to study the swelling percentage with increased 
concentrations of PRGF, HA, and CW to determine if there is a threshold in which the 
scaffold can no longer swell. 
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Figure 4.2 - Swelling percentage of GE and PHCE scaffolds upon hydration. 
 
4.4.2. Scanning electron microscopy  
 Scanning electron microscopy (SEM) revealed surface characteristic differences 
between GE and PHCE scaffolds, as well as mineralized and non-mineralized scaffolds 
(Figure 4.3). GE scaffolds appear to have a smoother material surface with smaller pores 
while PHCE scaffolds contain a rougher surface with larger pores. Since GE scaffolds are 
only composed of gelatin, it is expected that they exhibit a more uniform surface 
composition. The addition of growth factors and nanofillers for PHCE scaffolds alter the 
scaffold characteristics by having a presence of the added molecules on the surface as well 
as a larger pore size. It is hypothesized that the small spheres and rougher surface 
visualized in Figure 4.3B is attributed to the incorporated nanofillers (HA and CW) present 
on or near the surface of the scaffold. After mineralization, GE-M scaffolds showed small 
clusters of mineral nucleation while PHCE-M scaffolds exhibited a more uniform 
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attraction. One of the aims of this dissertation is to evaluate differences between 
mineralized and non-mineralized scaffold protein release, mechanical properties, and 
cellular response to understand any added benefit to the nucleation of crystals to the 
scaffold surface.   
 
 
Figure 4.3 - SEM of (A) GE, (B) PHCE, (C) GE-M, and (D) PHCE-M scaffold surfaces. 
Scale bars at 100 µm. 
 
4.4.3. Alizarin Red S staining 
 Alizarin Red S staining was performed on GE and PHCE scaffolds before and 
directly after mineralization (Day 0). ARS was also performed on all scaffold types after 
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21 days incubation in 1x PBS to asses any potential loss of mineral content as a result of 
scaffold degradation (Figure 4.4). Results indicate a significant increase (p<0.05) in 
mineral content between GE and PHCE scaffolds. This is expected since HA was 
incorporated into the PHCE scaffolds and not within GE scaffolds. The ARS assay was not 
sensitive enough to detect statistical differences between mineralized and non-mineralized 
scaffolds. There were no significant differences (p<0.05) in absorbance values between all 
scaffolds at day 21. In fact, all day 21 absorbance values (with the exception of GE-M) 
were significantly lower (p<0.05) than day 0 values for the same scaffold type. This 
suggests that some minerals are being released as the scaffold degrades. It is unclear as to 
why the GE scaffolds had lower values at day 21 when compared to day 0. It was noticed 
that ARS bound to GE scaffolds to some degree and is possible that this baseline affinity 
binding was decreased as the scaffold degraded.  
 
 
Figure 4.4 - ARS of GE and PHCE scaffolds directly before and after mineralization (Day 
0) and of all scaffolds after 21 days incubation in 1x PBS. 
67 
 
4.4.4. Scaffold protein release 
 One of the main considerations to take into account when designing any tissue 
engineering scaffold is degradation. Scaffolds that degrade too quickly will fail early when 
implanted, while extremely slow degrading scaffolds do not allow a favorable environment 
for cells to remodel and replace the construct with new tissue. In this study, the Pierce 
BCA assay was used to quantify amounts of general protein released from the lyophilized 
composite gelatin sponges into solution. This data provides some insight into scaffold 
degradation in that as the scaffold degrades, it releases its protein contents.  
 In order to understand the degree to which the scaffold is breaking down, we first 
must know the original total protein content of the 6 mm discs. The original total protein of 
each disc was quantified by allowing non cross-linked gelatin (G) and 
gelatin+PRGF+HA+CW (PHC) scaffolds to fully degrade in PBS. There was no statistical 
difference (p<0.05) between the average original total protein content of the G (1022 µg) 
and PHC (1102 µg) scaffolds (Figure 4.5). It was expected that the PRGF containing 
scaffolds would record higher initial protein values since it was an additive to the existing 
gelatin solution. However, the small amounts of PRGF added (3.33 mg/mL) may not be 
enough protein to record detectable differences when compared to the majority component 
of gelatin (30 mg/mL). It is hypothesized that if a higher concentration of PRGF was added 
to the scaffolds, then a detectable increase in protein content would be observed.     
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Figure 4.5 - Original total protein content of non cross-linked scaffolds. 
 
 Knowing that the G and PHC scaffolds contain the same amount of total protein, 
we can now directly compare GE, GE-M, PHCE, and PHCE-M release kinetics over 21 
days without standardization. Figure 4.6A below graphically displays scaffold protein 
release quantification over 21 days such that a comparison can be made between which 
scaffolds released the most protein per time point. Interestingly, all scaffold types released 
similar amounts of protein (no significant difference, p<0.05) on days 1, 7, and 14. On the 
other hand, PHCE-M scaffolds released significantly more protein (p<0.05) on days 4 and 
21 when compared to GE, GE-M, PHCE and GE, GE-M scaffolds, respectively. This data 
suggests that PHCE-M scaffolds are degrading and releasing its contents at a faster rate 
than all other scaffolds, particularly on days 4 and 21.   
 The same data presented in Figure 4.6A is graphed differently (Figure 4.6B) to 
examine the protein release kinetics of a given scaffold composition over 21 days 
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incubation in PBS. For GE scaffolds, there was a significant decrease (p<0.05) in release 
on day 21 when compared to days 1, 4, and 14. However, a significant increase (p<0.05) in 
release was observed between days 7 and 14. GE-M scaffolds exhibited a similar 
significant decrease (p<0.05) in release on day 21 when compared to days 1, 4, and 7. Day 
14 release from GE-M was also significantly lower than day 1. This suggests that most of 
the release of GE-M scaffolds occurs within the first 7 days. For PHCE scaffolds, day 1 
release was significantly higher (p<0.05) than all other time points. Day 4 PHCE release 
was also significantly higher (p<0.05) than day 21. This data supports that there is a bulk 
release of PHCE scaffolds on day 1, followed by sustained release of protein at lower 
doses. For PHCE-M scaffolds, protein release on day 4 was significantly higher (p<0.05) 
than on days 7, 14, and 21. These results suggest that for PHCE-M scaffolds, there is 
normal release on day 1, while day 4 releases more compared to the following time points.  
Overall, these results show that each scaffold has its own protein release profile which 
indicates that mineralization can alter the scaffold degradation.  
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Figure 4.6 - Comparison of protein released A) by scaffolds at a given time point and B) 
over time, specific to each scaffold. 
 
 The protein release analysis presented up to this point focused on release kinetics of 
a particular scaffold at a specific time point. However, the overall cumulative protein 
release from each scaffold over the 21 days has yet to be discussed. Using the same data 
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presented above, the cumulative protein release as a concentration and percent of total 
protein released from each scaffold was summed and graphed (Figure 4.7). These graphs 
illustrate that starting on day 4, PHCE-M release more protein overall compared to all 
other scaffold types. Specifically looking at Figure 4.7B, we are able to demonstrate that 
PHCE-M scaffolds are releasing 5% of its total protein content between days 14 and 21 
while all other scaffold types are only releasing approximately 1%. This suggests that 
PHCE-M scaffolds are capable of sustained release of high quantities of protein even at 
later time points. 
 
 
72 
 
 
Figure 4.7 - Cumulative protein release measured as A) concentration and B) percent of 
total protein from scaffolds over 21 days. 
 
 In order to gain a relative understanding of protein quantity released by each 
scaffold, day 21 cumulative released amounts were compared to non cross-linked original 
total protein content to determine the percentage of protein released (Figure 4.8). GE, GE-
M, PHCE, and PHCE-M released 19.5%, 21.4%, 16.9%, 30.7%, respectively. Cumulative 
protein release from PHCE-M scaffolds was significantly higher (p<0.05) than all other 
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scaffolds. GE-M cumulative release was also significantly higher (p<0.05) than only 
PHCE release. These results show that PHCE-M scaffolds are capable of 30.7% release of 
its incorporated protein within the first 21 days and that mineralization of PHCE scaffolds 
increases protein release. The increase in mineralized scaffold protein release could be 
attributed to the gaps that form during mineralization between the inorganic particles and 
the polymer matrix which can provide channels for the penetration of water [128]. 
Continuous elevated sustained release of protein is ideal for tissue engineering scaffolds, 
rendering PHCE-M scaffolds a viable candidate for tissue regeneration constructs.   
 
 
Figure 4.8 - Cumulative protein released (after 21 days) as a percentage of the original 
total protein content. 
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4.4.5. Growth factor analysis  
Understanding which growth factors are present in liquid PRP and PRGF 
(lyophilized PRP) are important when analyzing cellular responses to scaffolds. Although 
PPP was not used in this study, a growth factor analysis of PPP was performed to 
understand the composition and difference between PRP and PPP. In this study, a PRGF, 
PRP, and PPP growth factor profile curve was obtained from dilutions of pure PRGF (100, 
50, 10, 1, and 0.1 mg/mL), PRP (1:10 and 1:20), and PPP (1:10 and 1:20) in DI water. 
Although these profiles do not encompass all growth factors present in PRGF, PRP, and 
PPP, it does provide an analysis of the several key factors (Figure 4.9). Of the analytes 
used, only two growth factors (G-CSF and FGF-1) were not detected and therefore not 
present in PRGF, PRP, or PPP. The highest concentrations of growth factors detected in 
PRGF and PRP were HGF and VEGF-A. Lower amounts of EGF, FGF-2, and VEGF-C 
were also present. IL-8 and VEGF-D were detected at even lower concentrations. As 
expected, the dilutions of PRGF and PRP resulted in low recorded values for all growth 
factors. However, PRGF (100 and 50 mg/mL) and PRP (1:10 and 1:20) provide a strong 
profile of growth factors present. It was expected that PRGF and PRP report the same 
growth factor profile since PRGF is a lyophilized version of PRP. This demonstrates that 
of the factors analyzed, PRP lyophilization does not affect the growth factors present in 
PRGF. It was noticed that the concentrations for each growth factor within PRP (1:10 and 
1:20) more closely resemble the PRGF values at 10 mg/mL dilution. Since PRP is a liquid, 
it is measured in volume when administered clinically and experimentally. Alternatively, 
PRGF is measured as a weight/volume concentration since it is a powdered substance. This 
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analysis suggests that the concentrations of growth factors present in a 1:10 and 1:20 
dilution of PRP is comparable that found in 10 mg/mL of PRGF. Table 4.1 presents the 
mean value of all growth factor concentrations within PRGF, PRP, and PPP dilutions with 
PRP (1:10 and 1:20) and PRGF (10 mg/mL) highlighted to show the comparison of similar 
growth factor concentrations. As summarized in Chapter 2 and table 2.1, PRGF 
components have positive effects on angiogenesis and bone remodeling both in vivo and in 
vitro. PPP was not expected to contain high concentrations of growth factors since there 
are a low number of platelets. The analysis of PPP dilutions revealed the low presence of 
FGF-2, HGF, VEGF-A, VEGF-C, and VEGF-D. The growth factor profile of PPP (1:10) 
more closely resembles that of PRGF (1 and 0.1 mg/mL), both highly diluted solutions. 
The PPP growth factor analysis profile is also presented in Table 4.1. 
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Figure 4.9 - Growth factor analysis of (A) PRGF, (B) PRP and PPP dilutions. 
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Table 4.1 - Average growth factor concentration (pg/mL) in PRGF, PRP, and PPP 
dilutions. The average of the lowest standard is presented as the minimum level of 
detection (Min Detection).  
 
  EGF FGF-2 IL-8 HGF VEGF-A VEGF-C VEGF-D 
PRGF100 121.0 93.6 20.5 700.2 970.8 48.1 13.8 
PRGF50 105.3 78.0 19.3 569.2 789.8 51.9 25.6 
PRGF10 28.9 12.6 3.9 124.3 105.6 25.6 7.2 
PRGF1 0.0 9.0 0.2 12.2 4.4 1.2 0.0 
PRGF0.1 0.0 9.0 0.0 1.1 0.0 0.0 0.0 
PRP 1:10 57.3 22.8 4.9 135.8 156.4 30.1 1.0 
PRP 1:20 42.4 15.7 3.2 100.4 99.3 22.7 0.9 
PPP 1:10 0.0 8.3 0.0 12.7 0.0 1.5 0.8 
PPP 1:20 0.0 8.1 0.0 8.9 0.8 0.4 0.1 
PHC 13.9 10.1 0.0 4.3 9.4 2.4 0.2 
Min Detection 2.7 13.7 1.4 27.2 13.7 6.8 6.9 
 
 
Multiplexer analysis of the uncross-linked PHC scaffolds provides the growth 
factor profile of the original content of each scaffold. There were detectable amounts of all 
growth factors in PHC scaffolds with concentrations ranging between PRGF 10 mg/mL 
and PRGF 1 mg/mL (Table 4.1). The reported concentrations of growth factors are 
expected since 3.33 mg/mL PRGF was used to fabricate PHCE scaffolds. These results 
confirm that PRGF can successfully be incorporated within lyophilized gelatin sponges 
and the presence/concentrations of growth factors (specifically EGF) are maintained. 
Multiplexer analysis of PHCE and PHCE-M scaffold release over 21 days showed no 
quantifiable traces of the above growth factors. It was expected that some growth factors 
would be detectable as the scaffold degraded and released its contents. This absence of 
measurable growth factors from scaffold release could be a result of a highly diluted 
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sample since 6 mm discs were incubated in 1 mL of PBS to assess degradation. In this 
instance, growth factors released from the scaffold become diluted in the high volume of 
PBS which may result in no detection (as evident of the dilutions of pure PRGF in Figure 
4.9).  It is also possible that there was not enough PRGF originally incorporated within the 
PHCE scaffolds such that any release is in small amounts and therefore not detected by the 
multiplexer. On the other hand, it could be stated that there is no detectable growth factors 
in the release because PRGF is simply not being released. This non-release of PRGF can 
potentially be an added benefit in that the scaffold is able to maintain the incorporated 
growth factors and constantly provide a bioactive surface for cells to attach, proliferate, 
and remodel. Future studies will focus on which of these situations is occurring with 
lyophilized gelatin/PRGF sponges. This will be conducted by degrading the scaffold in less 
solution (to remove the possibility of severe dilution) and by incorporating higher initial 
concentrations of PRGF.  
4.4.6. Uniaxial compression testing 
 Uniaxial compression testing using a platen system was used to record peak load 
(N) and Young’s modulus (MPa) for compression of scaffolds incubated in media for up to 
21 days. Day 4 of mechanical testing was not reported as the mechanical properties 
showed more significant changes weekly. Figure 4.10A reports and analyzes the peak 
loads of each scaffold type at a given time point. At days 1 and 14, GE-M scaffolds 
exhibited significantly higher (p<0.05) peak loads than all other scaffolds. On days 7 and 
21, GE and GE-M had significantly higher (p<0.05) peak values than PHCE and PHCE-M 
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scaffolds. This data suggests that throughout 21 days, PHCE and PHCE-M scaffolds 
consistently report significantly lower (p<0.05) peak load values (0.1 – 1.0 N) when 
compared to GE and GE-M scaffolds (1.0 – 2.7 N).  
The same data was graphed differently to compare peak values of a given scaffold 
throughout 21 days incubation (Figure 4.10B).  For GE scaffolds, day 1 and day 14 
produced the significantly lowest and highest (p<0.05) values, respectively. For GE-M 
scaffolds, incubation for 14 days in media produced the highest (p<0.05) peak load value 
compared to all other days. Day 1 for PHCE scaffolds was significantly lower (p<0.05) 
than all other days while PHCE-M scaffolds showed no significant changes (p<0.05) in 
peak load throughout 21 days. With the exception of PHCE-M scaffolds, this data shows 
that scaffolds have lower peak loads at earlier time points (days 1 and 7) when compared to 
later time points (day 14). 
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Figure 4.10 - Peak load of scaffolds A) at a given time point and B) over 21 days 
incubation in media. 
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 Figure 4.11A reports and analyzes the compressive modulus of each scaffold type 
at a given time point. After 1 day incubation, PHCE-M scaffolds had a significantly lower 
(p<0.05) modulus than all other scaffold types. In fact, GE scaffolds had significantly 
higher (p<0.05) values than GE-M and PHCE-M. For day 7, GE scaffolds reported a 
significantly higher (p<0.05) modulus than both PHCE and PHCE-M scaffolds. After 14 
days incubation, GE and GE-M scaffolds had significantly higher moduli when compared 
to PHCE-M scaffolds. Day 14 shows a higher modulus for GE-M scaffolds when 
compared to GE and PHCE-M scaffolds. Overall PHCE-M scaffolds report lower Young’s 
modulus values (1.3 - 1.6 MPa) when compared to GE and GE-M scaffolds (1.6 - 3.2 
MPa). One aim of this study is to create a scaffold with similar mechanical properties to 
that of native bone healing tissue. The first stages of bone healing involve granulation 
tissue and hyaline cartilage (soft tissue) formation before any mineralization occurs. The 
Young’s modulus of cartilage in the literature is at similar low values of 0.5-0.8 MPa while 
mature bone and other materials are in the GPa range [129].  Zhang et al. report similar 
low compressive Young’s modulus values (0.3 – 3.0 MPa) for gelatin-hyaluronic acid 
composite freeze-dried sponges intended for soft tissue engineering applications [127]. The 
low range of modulus values of these scaffolds provide a mechanical microenvironment 
similar to that found in the early stages of bone healing.  
 Evaluating statistical differences in Young’s modulus of a given scaffold over 21 
days will provide a different viewpoint on how each scaffold’s properties change over 
time. To achieve this, the same modulus data was graphed with the legend and x-axis 
switched and statistics were performed (Figure 4.11B). The modulus for GE and PHCE 
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scaffolds significantly decreased (p<0.05) after 21 days incubation in media while their 
mineralized counterparts showed no significant changes (p<0.05) in modulus within the 
same time period. This suggests that mineralized scaffolds maintain their modulus 
throughout incubation while non-mineralized scaffolds show a decrease. It is also noticed 
from Figure 4.11A that the initial modulus (Day 1) of mineralized scaffolds is significantly 
lower (p<0.05) than non-mineralized scaffolds. This could attribute to the decrease in 
modulus as seen in non-mineralized scaffolds since they start off at higher values.   
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Figure 4.11 - Young’s modulus for compression of A) scaffolds at a given time point and 
B) a given scaffold over 21 days incubation in media. 
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4.5. CONCLUSION 
 Lyophilized gelatin sponges were enhanced with PRGF, HA, and CW and cross-
linked during gelation. Both control GE scaffolds and PHCE scaffolds swelled 50% their 
original size upon hydration. After fabrication, scaffolds were subsequently mineralized to 
create a bone-like surface. GE scaffolds nucleated minerals in more of a sparse aggregate 
manner while PHCE scaffolds showed more uniform mineralization across the surface. 
The highest concentrations of growth factors detected in PRGF and PRP were HGF and 
VEGF-A. As presented in Table 2.1, VEGF and HGF are known to increase angiogenesis, 
osteoblast proliferation, and endochondral ossification which are all vital to bone 
regeneration. The growth factor profile of PPP (1:10) more closely resembled that of 
PRGF (1 and 0.1 mg/mL), both highly diluted solutions. The BCA protein assay showed 
that PHCE-M scaffolds degraded faster and released 30% of its original protein content. 
Although PHCE-M scaffolds degraded the fastest, no PRGF growth factors were 
detectable after analyzing contents of released protein. However, multiplexer analysis did 
reveal the successful incorporation of PRGF within uncross-linked PHC sponges. The 
lower compression moduli values of PHCE and PCHE-M scaffolds are comparable to 
moduli values of tissues found in the early stages of bone healing. These findings suggest 
that PHCE and PHCE-M scaffolds have potential for use as early bone healing tissue 
scaffolds; however, in vitro cellularized studies are required to assess cellular responses to 
the various composite porous sponges. 
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5. IN VITRO RESPONSE OF MG-63 OSTEOBLAST-LIKE CELLS 
CULTURED ON LYOPHILIZED GEALTIN SPONGES 
ENHANCED WITH PRGF, HA, CW, AND A BONE-LIKE 
MINERAL SURFACE   
 
5.1. ABSTRACT 
 The development of three-dimensional porous scaffolds with enhanced osteogenic 
and angiogenic factors are important characteristics to consider when fabricating scaffolds 
intended for bone tissue engineering, specifically early bone healing. The previous study 
demonstrated the advantages of PHCE and PHCE-M scaffolds which included: swelling 
potential, successful incorporation of growth factors, controlled release properties, and 
similar compression moduli as tissues present in early bone healing. In this study, GE, GE-
M, PHCE, and PHCE-M scaffolds were dynamically seeded with MG-63 osteoblast like 
cells for 21 days and cellular responses to scaffolds as well as scaffolds response to cells 
were evaluated. Specifically, cell proliferation, attachment, infiltration, protein/cytokine 
secretion (osteocalcin, osteopontin, IL-6, IL-1β, TNF-α), and scaffold compressive 
mechanical properties (peak load and modulus) were evaluated.  Scaffolds were cross-
linked with EDC, a potentially cytotoxic carbodiimide. As such, a basic cytotoxicity 
experiment was performed to determine if uncross-linked EDC is harmful to the cells. 
Results indicated that uncross-linked EDC in media at any concentration (from 0.8 – 50 
mM) is cytotoxic to MG-63 cells. Since cells on scaffolds were viable for up to 21 days in 
this study and up to 90 days in Chapter 3, it was concluded that there is no residual harmful 
uncross-linked EDC which will negatively affect cell response. Both DAPI staining and 
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MTS cell proliferation assay reported increased proliferation of cells on GE-M and PHCE 
scaffolds, and decreased proliferation on PHCE-M scaffolds. DAPI imaging showed a 
noticeable increase in initial cell attachment and infiltration of PHCE and PHCE-M 
scaffolds on day 1. GE-M scaffolds also attached more cells than the GE control. MTS 
results indicated that PHCE scaffolds increased cell proliferation after 4 and 7 days when 
compared to GE controls. It also showed that the addition of a mineral coating to GE 
scaffolds increases cell proliferation at day 4. Analysis of MG-63 protein/cytokine 
secretion suggests that the cells are responding in a bone regenerative fashion when seeded 
on all scaffolds, as evidence of osteocalcin secretion. Little to no secretion of osteopontin, 
IL-1β, and TNF-α demonstrates that scaffolds are not influencing cells to secrete factors 
associated with bone resorption. Cells also secreted small amounts of IL-6 when seeded on 
scaffolds for 1 day. IL-6 is a cytokine known to have both bone regenerating and resorbing 
effects. The compressive mechanical properties of cellularized scaffolds did not differ 
much from acellular scaffolds. There were a few exceptions where cells remodeled the 
scaffold such that increased peak load (PHCE, PHCE-M, GE-M day 14) and modulus (GE 
and PHCE day 21) were recorded. The combined results increased cellular attachment, 
infiltration, and bone regenerative protein/cytokine secretion by cells on GE-M scaffolds 
support the addition of a bone-like mineral surface to GE scaffolds. Cellularized PHCE 
and PHCE-M scaffolds report similar advantages as well as Young’s modulus values in the 
range of native tissues present in the early stages of bone healing. These results suggested 
that the developed PHCE and PHCE-M scaffolds exhibit good cellular response and 
mechanical properties for early bone healing applications. 
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5.2. INTRODUCTION 
 As previously mentioned, designing scaffolds intended for bone tissue engineering 
must satisfy certain criteria such as: biocompatibility, degradability, porosity, mechanical 
integrity, osteoconductivity, and osteoinductivity. Chapter 3 illustrated that porous 
lyophilized gelatin sponges enhanced with PRGF, HA, and CW, allow the attachment 
(bioactivity), infiltration (porosity), and secretion of bone-like matrix (osteoconductivity) 
after static culture with MG-63 osteoblast-like cells. Chapter 4 further analyzed and 
reported positive results for protein release, mechanical integrity, and the ability to 
incorporate osteogenic factors within mineralized and non-mineralized PHCE scaffolds. 
The aim of this study is to analyze the cellular response of MG-63 cells dynamically 
seeded on GE, GE-M, PHCE, and PHCE-M scaffolds. The motive for dynamic cell 
seeding was to provide an environment where cells are not “forced” onto the scaffold (as 
seen in static cell seeding). In this seeding technique, the scaffolds were floating in a cell 
suspension in a rotary cell culture system (bioreactor) where they can come in contact with 
each other and if the scaffold is bioactive, it will promote cell attachment and infiltration. 
Since scaffolds are mineralized and/or incorporated with a variety of growth factors, it is 
hypothesized that cells will proliferate and secrete proteins/cytokines differently on various 
scaffolds. Osteocalcin and osteopontin are the main proteins secreted by osteoblasts 
indicative of bone regenerative and bone resorptive behavior, respectively. In addition to 
detecting osteocalcin and osteopontin, the secretion of other bone regenerating (IL-6) and 
resorbing factors (IL-6, IL-β, and TNF-α) were recorded. IL-6 is a controversial cytokine 
in that it is has been found to be associated with both bone resorption and regeneration 
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(Table 5.1). This study also compares acellular and cellular mechanical properties to 
determine what affect, if any, cells will have on the peak load and modulus of lyophilized 
sponges.   
5.3. MATERIALS AND METHODS  
5.3.1. Fabrication of gelatin composite sponges 
Gelatin+EDC (GE) and PRGF+HA+CW+EDC (PHCE) lyophilized sponges were 
fabricated and subsequently mineralized (GE-M and PHCE-M) as previously outlined in 
Chapter 4, Sections 4.3.1 and 4.3.3. For all in vitro cell studies, MG-63 cells (human 
osteoblast-like cells derived from an osteosarcoma) were used. MG-63 cells behave similar 
to osteoblasts with their attachment, migration, proliferation, and bone matrix production. 
5.3.2. Cytotoxicity of uncross-linked EDC 
To determine the cytotoxic effect of potential residual uncross-linked EDC, a cell 
proliferation assay was performed and cells were exposed to various concentrations of 
uncross-linked EDC. Briefly, MG-63 cells were seeded subconfluently in a 96-well plate at 
5,000 cells/well in 100 µL of control media (DMEM high glucose, 10% fetal bovine 
serum, 1% penicillin/streptomycin). Following the adhesion of cells to the well plate 
(approximately 1 hour), control media was removed and replaced with conditioned media 
(control media supplemented with 0, 0.8, 1.5, 3.1, 6.3, 12.5, 25, and 50 mM EDC). An 
MTS assay (Cell-Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay, Promega, 
Madison,WI, USA) was performed on days 1, 4, and 7 (with media changes on days 1 and 
89 
 
4) to determine mean proliferative cell count. At the termination of each time point, 
conditioned media in each well was removed and replaced with 100 µL of control media 
and MTS was performed per manufacture’s protocol.  
5.3.3.  Cell seeding on scaffolds 
 In Chapter 3, MG-63 cells were statically seeded on 6 mm-sized scaffold discs in a 
96-well plate. Although the static method produced sufficient preliminary results, a more 
in vivo-mimicking method is appropriate for cell seeding. For this experiment, a dynamic 
(floating scaffold) cell seeding technique was used to not “force” the cells to attach to the 
scaffold. To accomplish this, a rotary cell culture system (Synthecon, Inc.) was used. Four 
bioreactors (60 mL volume capacity each) were autoclaved and attached to the rotary 
system in a sterile incubator for dynamic cell seeding. Twelve 6 mm discs of each scaffold 
type (GE, GE-M, PHCE, PHCE-M) were disinfected (30 mins ethanol followed by three 
10 min washes in 1x PBS) and transferred to separate bioreactors. MG-63 osteoblast-like 
cells were suspended in control media at a concentration of 50,000 cells/mL. 60 mL of this 
cell solution was then added to each bioreactor containing disinfected scaffolds. 
Bioreactors with scaffolds floating in cell suspension were placed in an incubator with 
standard culture conditions (37°C and 5% CO2) and turned on (42 rpm) to allow 
circulation of cell suspension solution and tumbling of floating scaffolds. After dynamic 
cell seeding for 6 hours, scaffolds were then transferred from the bioreactor to a 96-well 
plate containing 150 µL of culture media and statically cultured for 1, 4, 7, 14, 21 days 
with media changes every 3 days. Cellular scaffolds were characterized for attachment, 
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proliferation, infiltration, secretion of osteogenic factors, and compressive mechanical 
properties. 
5.3.4.  Scanning electron microscopy 
After 1, 4, 7, 14, and 21 days in culture, cellularized scaffolds were fixed in 1 mL 
of 10% formalin and stored at 4°C until further analysis. Prior to imaging, cellularized 
scaffolds were removed from formalin, briefly rinsed in PBS and DI water, subjected to 
ethanol dehydration (10 minute soaks in 30, 50, 70, 90, and 100 % ethanol, subsequently), 
and air dried overnight. All dry samples were mounted on aluminum stubs, sputter coated 
in gold for 70 seconds, and examined using a JEOL JSM-5610LV scanning electron 
microscope (accelerating voltage at 20 kV). 
5.3.5. Cell attachment and proliferation 
After dynamic MG-63 cell seeding, GE, GE-M, PHCE, and PHCE-M scaffolds 
were cultured for 1, 4, and 7 days in a 96-well plate with 175 µL of control media with 
media changes on days 1 and 4. The MTS cell proliferation assay mentioned in Section 
5.3.2 was also used to determine proliferative cell count on scaffolds. After each time 
period, scaffolds were transferred to a new well containing 100 µL of control media. 20 µL 
of MTS+PMS solution was then added to the well containing the media plus scaffold and 
incubated for 1 hour at 37°C. 100 µL of this solution was then transferred to a new 96-well 
plate and absorbance read at 490 nm.  
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5.3.6. DAPI staining 
GE, GE-M, PHCE, and PHCE-M scaffolds were dynamically seeded with MG-63 
cells as described in Section 5.3.3. After 1, 4, 7, 14, and 21 days in culture, cellularized 
scaffolds were fixed in 1 mL of 10% formalin and stored at 4°C until further analysis. 
Scaffolds were prepared for DAPI staining as mentioned in Chapter 3, Section 3.3.4. 
Briefly, scaffolds were removed from formalin, immersed in sucrose solution 48 hours at 
4°C, suspended in frozen sectioning compound, and frozen at -70°C overnight. 60 µm 
slices were cryosectioned and transferred to microscope slides. Sample cross-sections were 
then stained with 4’-6-diamidino-2-phenylindole (DAPI) stain for 5 minutes and imaged 
using a UV fluorescent microscope to display the location of cell nuclei. As previously 
discovered, the ability to image cells via DAPI staining becomes increasingly difficult after 
weeks of culture. Therefore, only days 1 and 4 DAPI images are reported and serve as an 
indication to initial cell attachment and infiltration.  
5.3.7. Multiplexer analysis of secreted osteoblast factors 
GE, GE-M, PHCE, and PHCE-M scaffolds were dynamically seeded with MG-63 
cells and statically cultured for 1, 4, 7, 14, and 21 days. At each time point, media from 
each well was collected and analyzed for osteoblast secretion of osteocalcin, osteopontin, 
interleukin -1 beta (IL-1β), IL-6, and tumor necrosis factor-alpha (TNF-α). This detection 
and quantification was accomplished by using a Luminex MagPix multiplexer (fluorescent 
imager) with the MILLIPLEX® MAP Human Bone Magnetic Bead panel (containing the 
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above mentioned analytes). This technology is the same as described in Chapter 4, Section 
4.3.7.  
5.3.8. Uniaxial compression testing 
After 1, 4, 7, 14, and 21 days culture in media, cellularized scaffolds (6 mm diameter) 
of each scaffold type were subjected to compressive mechanical testing (as described 
Chapter 3, Section 3.3.5). Briefly, mechanical testing was conducted by using 2 flat metal 
platens and performed perpendicular to the scaffold surface without any circumferential 
constraints to allow for free lateral deformation. Scaffolds were removed from culture 
media, dabbed on a kimwipe to remove excess media/liquid, then placed on the flat metal 
surface (samples were still hydrated). Compression was performed as described in Chapter 
4, Section 4.3.8. Peak load (N) and Young’s modulus (MPa) were extracted and calculated 
using the graphical output from the MTS software TestWorks 4.0.  
5.3.9. Statistical analysis 
Statistical analysis was performed using JMP IN 9 statistical software (SAS Institute) to 
determine significant differences. Analysis of the data was based on a Kruskal-Wallis one-
way analysis of variance on ranks and a Tukey-Kramer pairwise multiple comparison 
procedure. The results are presented in mean ± standard deviation (SD). Samples were run 
at least in triplicates (n=3) to ensure statistical significance (p<0.05). 
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5.4. RESULTS AND DISCUSSION  
5.4.1. Cytotoxicity of uncross-linked EDC 
 EDC is a commonly used carbodiimide that has proven successful for cross-linking 
scaffolds while maintaining bioactivity [127, 130-132]. However, the MG-63 cellular 
response to potential exposure to any amount of uncross-linked EDC has not been 
determined. Figure 5.1 reports the MTS cell proliferation assay results of varying 
concentrations of EDC in media directly exposed to cells. It was determined that uncross-
linked EDC in any concentration (from 0.8 – 50 mM) is cytotoxic to MG-63 cells. This is 
an important finding because any residual uncross-linked EDC present on or within the 
scaffold will cause the cells to die. As shown in Chapter 3 and later in this chapter, cells 
remain viable on all EDC cross-linked sponges for up to 90 days, suggesting there is no 
uncross-linked residual cytotoxic EDC that is harmful to the cells.  For the control well 
(EDC 0 mM) there is a significant increase in cell proliferation from day 1 to 4 followed 
by a significant decrease in proliferation from days 4 to 7. Since MTS is commonly used as 
a cell viability assay, by quick glance of these results, one may conclude that cells began to 
die after 4 days of culture. However, by visual inspection of all the wells (conditioned and 
control), it was apparent that cells exposed to any concentration of EDC were in fact dying 
(cells balled up and floating). Cells in the control wells on day 4 and 7 were very 
confluent. The decrease in the MTS reading of 0 mM EDC on day 7 could be attributed to 
the decrease in the number of proliferating cells. As cells become confluent in the well 
plate (day 4), they stop proliferating and begin preparing to secrete factors conducive to 
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bone remodeling. Although both day 4 and 7 wells had a confluent layer of cells, day 7 
recorded a lower number of proliferating cells suggesting cells are not dying, but rather 
progressing to the next stage of secreting factors for bone remodeling. Analysis of media 
for bone remodeling markers is one method to confirm this hypothesis. 
 
 
Figure 5.1 - MTS cell proliferation assay with varying concentrations of EDC in media. 
 
 
5.4.2. Scanning electron microscopy 
 Scanning electron microscopy was performed on GE, GE-M, PHCE, and PHCE-M 
scaffolds after dynamic cell seeding and subsequent static culture for 1, 4, 7, 14, and 21 
days (Figures 5.2 and 5.3). Scaffolds were subjected to ethanol dehydration in order to 
image cellularized scaffolds. Ethanol dehydration is a procedure commonly used to prepare 
cellular scaffolds for imaging. However, since these sponges are hygroscopic in nature, 
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dehydration caused the scaffolds to shrink upon preparation for imaging. Therefore, the 
images presented here and in Chapter 3 are not representative of a fully hydrated swollen 
scaffold that cells are in contact with. Although this is the case, basic observations can still 
be made. One noticeable difference with the images presented in this chapter is the visual 
appearance of no cells attached to any scaffolds at any time point. In Chapter 3, cells 
attached more as spheres and were easily visualized via SEM. Later in the chapter, DAPI 
staining confirms the presence of cells on and within GE, GE-M, PHCE, and PHCE-M 
scaffolds. It is plausible that the dynamic cell seeding technique caused the cells to attach 
to and integrate with the scaffold better than static cell seeding (where spheres of cells 
were visualized). It is also possible that there are more cells within the scaffold rather than 
on the surface, in which case will not be captured via SEM. Since mechanical stress is a 
factor for bone development, it has been shown that osteoblasts respond differently to 
mechanical stimuli when compared to a static environment [133, 134]. Future studies 
could focus on the degree of cell attachment and infiltration into the scaffold under 
dynamic and static culture conditions. For GE, GE-M, PHCE, and PHCE-M scaffolds, it 
was also observed that the scaffold became less porous over 21 days. This could be due to 
the remodeling of the scaffold by the cells, however, more in depth cell experiments 
analyzing the surface and entire cellular scaffold will need to be conducted for any 
conclusive results.   
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Figure 5.2 - SEM of cellularized GE and GE-M scaffolds. Scale bars at 50 µm. 
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Figure 5.3 - SEM of cellularized PHCE and PHCE-M scaffolds. Scale bars at 100 µm. 
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5.4.3.  Cell attachment and proliferation 
 The MTS assay was again used to determine the proliferative nature of cells 
dynamically seeded and subsequently statically cultured on scaffolds. MTS was also 
performed on acellular scaffolds of each type to determine any background or baseline 
values. As expected, MTS values for all acellular scaffolds ranged from 0 to 90 cells, 
indicating that there is no significant background or baseline value as a result of the MTS 
solution interacting with the acellular scaffold.  Figure 5.4A reports the MTS values of 
cellularized scaffolds at a given time point. For day 1, there was no significant difference 
(p<0.05) in cell proliferation between all scaffold types. On day 4, both GE-M and PHCE 
scaffolds reported a significantly higher count of proliferative cells compared to GE and 
PHCE-M. Day 4 results offer contradicting effects of mineralization on GE and PHCE 
scaffolds. On day 4, a mineralized GE scaffold increases cellular proliferation when 
compared to a non-mineralized GE scaffold. The opposite effect is observed for PHCE 
scaffolds where a non-mineralized PHCE scaffold reports a higher cell proliferation count 
compared to its mineralized counterpart. By day 7, there was no detection of proliferating 
cells on PHCE-M scaffolds, while PHCE scaffolds showed increased proliferation when 
compared to the GE scaffolds. These results indicate that PHCE scaffolds increase cell 
proliferation after 4 and 7 days when compared to GE controls. It is also evident that the 
addition of a mineral coating to GE scaffolds increases cell proliferation on day 4.  
 The same MTS data was graphed differently to analyze the statistical differences of 
cell proliferation on a given scaffold over 7 days (Figure 5.4B). The only scaffold that 
recorded a significant difference (increase, p<0.05) in cell proliferation was PHCE after 4 
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and 7 days culture. An unexpected result evident in both graphs was the significantly low 
(p<0.05) cell proliferation count on PHCE-M scaffolds. As DAPI will confirm in the 
following section, cells are abundant and present throughout PHCE-M scaffolds. This 
interesting observation poses some unique questions for future studies, “Why doesn’t the 
MTS assay register cells on PHCE-M scaffolds?”, “Are cells not proliferating on PHCE-M 
scaffolds?”, “Do cells on PHCE-M scaffolds quickly convert to a non-proliferative state?” 
When osteoblasts are present in an environment conducive to bone formation, the cells will 
stop proliferating and begin to secrete bone matrix. It is known that mature osteoblasts also 
have the ability to undergo apoptosis or become integrated within the mineral matrix to 
become osteocytes. It is a possibility that the PHCE-M scaffolds contain enough Ca-P such 
that osteoblasts are not scrambling to rebuild bone, but are rather content after attaching 
and begin integrating with the mineralized scaffold. This could also explain the non-
proliferative state of osteoblasts and the low cell count reported by MTS.  
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Figure 5.4 - MTS of cells cultured A) on each scaffold at a given time point and B) on a 
given scaffold for 7 days.  
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5.4.4. DAPI staining 
 Cell attachment and more importantly, infiltration into all scaffolds, was analyzed 
via DAPI staining after dynamic seeding followed by static culture for 1 and 4 days 
(Figure 5.5). The control GE scaffolds attached fewer cells than all other scaffold types, 
but did show appropriate cell infiltration after days 1 and 4. Cell infiltration into GE 
scaffolds is most likely attributed to the dynamic cell seeding method, since in Chapter 3, 
cells statically seeded on GE scaffolds primarily remained on the surface. A visual increase 
in cell attachment at the surface was observed for GE-M scaffolds suggesting that the 
minerals nucleated on the scaffold surface provide additional cell adhesion sites for 
osteoblasts. After 4 days in culture, cells were present throughout the entire scaffold 
indicating successful cell migration. Both PHCE and PHCE-M showed a large number of 
cells present throughout the scaffold on days 1 and 4. This increased cell attachment and 
infiltration was also reported for PHCE scaffolds in Chapter 3 using the static cell seeding 
method. This suggests that PHCE scaffolds increase initial cell attachment and infiltration 
independent of the cell seeding technique. Although there is no visual difference of cell 
attachment or infiltration between PHCE and PHCE-M scaffolds, there is a noticeable 
increase in initial cell attachment and infiltration when compared to GE and GE-M 
scaffolds on day 1. Even though cells on scaffolds are not clearly visible on the SEM 
images or detectable on PHCE-M scaffolds via MTS assay, DAPI results confirm the 
presence and viability of cells for up to 4 days.  
102 
 
 
Figure 5.5 - DAPI staining of mineralized and non-mineralized GE and PHCE scaffolds 
after dynamic cell seeding and subsequent static culture for 1 and 4 days. 
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5.4.5. Multiplexer analysis of secreted osteoblast factors 
 After 1, 4, 7, 14, and 21 days of MG-63 cell culture on scaffolds, osteoblast 
secretion of osteocalcin, osteopontin, IL-1β, IL-6, and TNF-α were analyzed. At the tissue 
level, bone coupling (regeneration and resorption) is regulated through a large number of 
cytokines and proteins (some regenerative factors were presented in Table 2.1). These 
factors have a complex and overlapping effect such that bone regeneration and resorption 
can occur simultaneously depending on the need of the microenvironment. The exact roles 
of some factors, such as IL-6, are not clearly identified and have been found to have both 
resorbing and regenerating effects. TNF-α is primarily associated as a pro-inflammatory 
cytokine secreted by inflammatory cells. However, less commonly known, osteoblasts 
have the ability to synthesize and release TNF-α as a local regulator for osteoblast function 
[135]. The osteoblast secreted factors analyzed in this study are a mix of bone regenerating 
and bone resorbing markers which provide a comprehensive analysis of osteoblast 
response over 21 days culture on GE, GE-M, PHCE, and PHCE-M scaffolds. Table 5.1 
briefly summarizes some known functions of each of these factors. 
 
Table 5.1 - Role of multiplexer human bone panel analytes in bone remodeling. 
 
 
Function 
osteocalcin 
Marker for bone formation. Elevated secretion related 
to increase bone formation [136, 137] 
Osteopontin Bone resorption [138, 139] 
IL-1β Bone resorption [140, 141] 
IL-6 
Bone resorption [142-145] 
Osteoblast differentiation [146, 147] 
TNF-α Bone resorption [148, 149] 
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 Multiplexer analysis revealed no traces (reported values below lowest standard) of 
osteopontin or IL-1β secretion by MG-63 cells cultured for 21 days on any scaffold type. 
These are positive results since both of these factors are associated with bone resorption. 
TNF-α secretion was detected in very small quantities (0.2 – 0.4 pg/mL), specifically on 
day 1 of GE, GE-M, and PHCE scaffolds (Figure 5.6). The lowest standard was 0.2 pg/mL, 
which suggests that the release of 0.2 – 0.4 pg/mL is at the lowest concentration detectable 
using the multiplexer. These results suggest that some cells that attached to GE, GE-M, 
and PHCE scaffolds secreted low amounts of TNF-α after 1 day culture on scaffolds. 
Although TNF-α is associated with bone resorption, the low concentrations detected on 
day 1 are not indicative of a bone resorbing response. In the body, bone resorption and 
regeneration occur simultaneously. It is possible that some cells attached in certain highly 
mineralized areas and began secreting TNF-α to initiate the resorption of that specific area 
on day 1. However, since low amounts of TNF-α were only detected on day 1, this 
suggests that this may be an initial response of some cells which is no longer the 
conditions from days 4 to 21. When comparing TNF-α secretion of all scaffolds on a given 
day, there were no significant differences (p<0.05) observed. This shows that on a given 
day, there was not a scaffold that induced significant secretion of TNF-α compared to the 
others.  
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Figure 5.6 - Secretion of TNF-α by MG-63 cells cultured on each scaffold over 21 days. 
 
 Analysis of IL-6 cytokine secretion from cells showed some significant differences 
when comparing scaffold types as well as time points. After culture for 1 and 4 days, cells 
on GE-M scaffolds secreted significantly higher (p<0.05) amounts of IL-6 compared to all 
other scaffolds (Figure 5.7A). From days 7 to 21, all IL-6 release was below detectable and 
not significant (p<0.05) between scaffolds. Figure 5.7B graphs the secretion of IL-6 and 
statistically compares release over 21 days per scaffold type. These results show a common 
trend of significantly higher IL-6 secretion on day 1 for all scaffolds. As alluded to in 
Table 5.1, the effects of IL-6 within bone remodeling are not totally defined. The literature 
supports both theories of increased levels of IL-6 correlating to bone regeneration and 
resorption. This study did not investigate the bone remodeling effects of IL-6, but it clearly 
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demonstrated that cells seeded on GE-M scaffolds and cells seeded on any scaffold after 1 
day secrete significantly higher levels of IL-6.   
 
 
Figure 5.7 - IL-6 secretion by MG-63 cells comparing A) scaffold types at a given time 
point and B) each scaffold over 21 days. 
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Secretion of osteocalcin by MG-63 cells was detected for all scaffold types at all 
time points suggesting that the cultured cells are responding positively by promoting a 
bone regenerative environment. Figure 5.8A below shows the secretion of osteocalcin by 
cells on all scaffolds on a given day. There are several statistical differences which vary 
over 21 days. Briefly, the highest secretions of osteocalcin were recorded from cells on: 
GE & PHCE-M scaffolds on day 1; GE, GE-M, & PHCE-M scaffolds on days 4 and 7; 
GE-M scaffolds on day 14; and GE-M & PHCE on day 21. The most noticeable trend with 
this data is starting on day 4, cells on GE-M scaffolds consistently secreted high amounts 
of osteocalcin over 21 days. Osteocalcin secreted from cells cultured up to 21 days were 
also compared within each scaffold type (Figure 5.8B). For GE and PHCE-M scaffolds, 
osteocalcin secretion was highest on days 1, 4, and 7. Cells on GE-M scaffolds secreted 
lower amounts of osteocalcin on day 1 but then showed significant increases in secretion 
on days 4, 7, and 14. Constant levels of osteocalcin protein secretion were observed for 
PHCE scaffolds over 21 days. These results suggest that depending on the scaffold type, 
MG-63 cells will promote more bone regeneration at different time points within 21 days.  
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Figure 5.8 - Osteocalcin secretion by MG-63 cells comparing A) scaffold types at a given 
time point and B) each scaffold over 21 days. 
 
 
 
Table 5.2 was constructed to summarize the secretion of all factors by MG-63 cells 
on all scaffolds on each day. This table compiles and identifies which scaffolds induced the 
highest secretion of all factors on each day. For osteopontin, IL-1β, and TNF-α, all 
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scaffolds on each day induced the same amount of secretion (little to none). This is a 
desired result since these factors are associated with bone resorption. For osteocalcin, GE-
M scaffolds induced amongst the highest secretion from day 4 to 21, suggesting that these 
scaffolds would induce more bone regeneration within 21 days. For IL-6, GE-M scaffolds 
induced the highest secretion on day 1 and day 4 (along with PHCE-M). As previously 
mentioned, the role of IL-6 in bone remodeling is controversial. Therefore, in this study, it 
cannot be concluded if IL-6 relates to bone regeneration or resorption.  
 
Table 5.2 - List of scaffolds that induced the highest secretion of factors at a given day. 
 
 
Day 1 Day 4 Day 7 Day 14 Day 21 
osteocalcin 
GE 
 
 
PHCE-M 
GE 
GE-M 
 
 
GE 
GE-M 
 
PHCE-M 
GE-M 
 
GE-M 
PHCE 
osteopontin - - - - - 
IL-1β - - - - - 
IL-6 
GE-M 
 
GE-M 
PHCE-M 
- - - 
TNF-α - - - - - 
 
Table 5.3 was created to summarize the trends (increase or decrease) of osteoblasts 
factor secretion per scaffold over 21 days. All scaffolds showed decreases or low cell 
secretion of IL-6 and TNF-α at early time points (day 1 or 4). GE and PHCE-M scaffolds 
induced lower osteocalcin secretion after day 7 and 21, respectively. GE-M scaffolds 
induced increased levels of osteocalcin secretion after day 1, while cells on PHCE 
scaffolds secreted constant levels over 21 days.   
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Table 5.3 - Trend of secreted factors from MG-63 cells on scaffolds over 21 days. 
 
 
GE GE-M PHCE PHCE-M 
osteocalcin ↓ after day 7 ↑ after day 1 constant ↓ on day 21 
osteopontin - - - - 
IL-1β - - - - 
IL-6 ↓ after day 1 ↓ after day 1 ↓ after day 1 ↓ after day 1 
TNF-α ↓ after day 1 ↓ after day 1 ↓ after day 4 constant 
 
 Overall, the analysis of secreted MG-63 cell factors suggests that the cells are 
responding in a bone regenerative fashion on all scaffolds, as evidence of osteocalcin 
secretion. Little to no secretion of osteopontin, IL-1β, and TNF-α proves that the scaffolds 
are not influencing the cells to respond in a resorptive manner. Again, the early secretion 
of IL-6 may be indicative of early bone regeneration or bone resorption response. In either 
instance, IL-6 secretion was only noticed at early time points and diminished after day 1. 
Since natural bone has the ability to regenerate and resorb simultaneously, the secretion of 
a combination of bone remodeling factors may be detected within the bone 
microenvironment. However, this study demonstrates the strong presence of MG-63 
osteocalcin secretion (compared to other factors) that is consistent throughout 21 days of 
culture on all scaffolds.  
5.4.6.  Uniaxial compression testing 
 As previously mentioned in Chapter 4, day 4 of mechanical testing was not 
reported as the mechanical properties showed no differences between days 1 and 7 and 
significant changes weekly. To analyze compressive mechanical properties of cellularized 
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scaffolds, both peak load (N) and Young’s modulus (MPa) for compression were recorded. 
Figure 5.9A below graphically displays the peak load of each cellularized scaffold type at a 
given time point. This allows us to determine which scaffolds have superior/inferior 
mechanical properties at each day. For day 1, GE-M scaffolds had significantly higher 
(p<0.05) peak loads to only PHCE scaffolds. By day 7, only GE scaffolds showed 
significantly higher (p<0.05) values than PHCE and PCHE-M scaffolds. On day 14 PHCE 
scaffolds showed the lowest (p<0.05) peak load values while on day 21 GE-M scaffold 
showed the highest (p<0.05) peak load values when compared to all scaffolds. These 
results do not show any predictable trends, but more of a variation with scaffold 
performance when compared to each day.  
 To better understand the peak load of each scaffold as it degraded, the same peak 
load data above was graphed differently and statistics performed (Figure 5.9B). For GE 
scaffolds seeded with cells, day 14 of culture produced significantly higher (p<0.05) peak 
load values than at all other time points while day 7 was only higher (p<0.05) than day 1 
and 21. This suggests that for GE scaffolds, the cells strengthened the scaffold over 14 
days. Since there was no detection of osteopontin, the cells are not resorbing the GE 
scaffolds which lead us to believe that the decrease in peak load at 21 days is not attributed 
to cell remodeling, but possibly the degradation of the scaffold. For GE-M scaffolds, only 
day 7 peak load values recorded different (significantly lower, p<0.05) than all other time 
points. There were no significant differences (p<0.05) in peak load values for PHCE 
scaffold over 21 days suggesting that the cells remodeling the scaffold were providing a 
balance of scaffold degradation and support. For PHCE-M scaffolds, only day 14 peak 
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values were significantly higher than day 21 values. Compared to acellular peak load 
values presented in chapter 4, there are fewer trends observed. This variation in peak load 
for cellular scaffolds is expected since the cells will continuously remodel each scaffold 
uniquely by attaching, applying their own mechanical forces, remodeling the scaffold, and 
producing matrix. 
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Figure 5.9 - Peak load of A) cellularized scaffolds at a given time point and B) of a given 
cellularized scaffold over 21 days in culture. 
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 To compare acellular (Chapter 4) and cellular (Chapter 5) peak load results, data 
was combined, graphed, and statistically analyzed for significant differences (Figure 5.10). 
Statistics were only performed on data comparing acellular versus cellular scaffold 
properties on a given day. For GE scaffolds, only day 21 cellular scaffolds showed 
significantly lower (p<0.05) peak load values compared to acellular values. This suggests 
that for GE scaffolds, the addition of cells do not influence the compressive peak load 
properties until day 21. Comparing acellular and cellular GE-M scaffolds, day 1 reported 
no significant difference, day 7 cellular scaffolds had significantly lower (p<0.05) values, 
and both days 14 and 21 cellular scaffolds had significantly higher (p<0.05) values than 
their acellular counterparts. This suggests that for GE-M scaffolds, the addition of cells 
increases the peak load values after longer culture times (14 and 21 days). For both PHCE 
and PHCE-M scaffolds, only day 14 cellularized scaffolds reported a different 
(significantly higher, p<0.05) peak load when compared to acellular scaffolds at the same 
time point. With cells continuously remodeling the scaffolds, it is difficult to extract 
relationships. It does, however, appear that at one point (day 14) for PHCE and PHCE-M 
scaffolds, the cells are remodeling the scaffold in a fashion that increases the peak load 
compressive properties of the scaffold.   
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Figure 5.10 - Peak load comparison of acellular and cellularized scaffolds over 21 days. 
 
 The second mechanical property that was extracted from the testing data was 
Young’s modulus for compression. Figure 5.11A displays the modulus of cellularized 
scaffolds at a given time point. It was determined that at each time point, there were no 
statistical differences (p<0.05) between the moduli of all scaffolds. This data reveals that 
independent of scaffold type, at a given time point all scaffolds exhibit similar Young’s 
modulus for compression. The means of Young’s modulus for all cellularized scaffolds 
throughout 21 days in culture ranged from 1.9 – 3.8 MPa. Figure 5.11B graphs the same 
Young’s modulus data except in a form where statistics can compare the modulus of a 
given cellularized scaffold over the 21 days. Only cellularized GE scaffolds at day 21 had 
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significantly higher (p<0.05) moduli than day 7 scaffolds. All other scaffolds reported no 
significant changes (p<0.05) in moduli over the 21 days in culture.  
 
 
Figure 5.11 - Young’s modulus for compression of A) cellularized scaffolds at a given 
time point and B) of a given cellularized scaffold over 21 days in culture. 
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To compare acellular (Chapter 4) and cellular (Chapter 5) Young’s modulus 
results, data was combined, graphed, and statistically analyzed for significant differences 
(Figure 5.12). As mentioned for peak load combined results, statistics were only performed 
on data comparing acellular versus cellular scaffold properties on a given day. For non-
mineralized cellular scaffolds (GE and PHCE), the only significant difference (p<0.05) 
was noticed on day 21 where cellular scaffolds reported higher modulus values that 
acellular scaffolds. This data suggests that after 21 days, the cells are remodeling non-
mineralized scaffolds in a manner that ultimately increases the scaffold’s stiffness. GE-M 
scaffolds showed no significant differences (p<0.05) while PHCE-M scaffolds only 
showed a significantly higher (p<0.05) modulus for day 1 cellular compared to acellular 
scaffolds. Overall, the Young’s modulus for compression of mineralized scaffolds 
remained unaffected as a result of the addition of cells.  
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Figure 5.12 - Young’s modulus for compression comparison of acellular and cellularized 
scaffolds over 21 days. 
 
 Although PHCE and PHCE-M had similar or lower peak load and modulus values 
compared to GE and GE-M scaffolds, the gross physical appearance of the mechanical 
integrity of the scaffolds were strikingly different once subjected to compressive 
mechanical loading. After subjection to compressive mechanical testing, the GE and GE-M 
scaffolds were demolished into pieces while the PHCE and PHCE-M scaffolds remained 
intact after complete compression (Figure 5.13). Although these images do not provide any 
quantifiable data, it does offer insight to future mechanical integrity studies that go beyond 
peak load and Young’s modulus for compression. It is clear that the addition of PRGF, 
HA, and CW to gelatin sponges allowed the scaffold to remain intact after maximum 
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compression, however, the degree to which each individual component contributed is a 
direction of future research.   
 
 
Figure 5.13 - Example of 21 day cellularized (A) GE and (B) PHCE scaffolds after 
complete compression post mechanical testing. GE-M and PHCE-M are not pictured as 
their gross appearances were similar to their non-mineralized counterparts. 
 
5.5. CONCLUSION 
Lyophilized gelatin sponges were enhanced with PRGF, HA, and CW, cross-linked 
during gelation, and subsequently mineralized to create a bone-like surface. This study 
presents several analyses of MG-63 cell response to scaffolds and scaffold response to 
cells. Chapter 3 concluded that MG-63 cells were viable on scaffolds for up to 90 days. 
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Since Chapter 4 determined that PHCE-M scaffolds release about 30% of their original 
protein, a basic EDC cytotoxicity assay was performed. It was determined that uncross-
linked EDC in any concentration (from 0.8 – 50 mM) is cytotoxic to MG-63 cells. 
Therefore, since cells on scaffolds survived for up to 21 days in this study, it can be 
concluded that there is no residual harmful uncross-linked EDC which will affect cell 
response. Upon SEM examination of cells on scaffolds, it is believed that the dynamic cell 
seeding technique enhances cell infiltration and potentially cell integration with the 
scaffolds since individual cells were not discernible on the scaffold surface. Both DAPI 
and MTS confirmed the presence and viability of cells cultured on scaffolds. DAPI 
imaging showed a noticeable increase in initial cell attachment and infiltration of PHCE 
and PHCE-M scaffolds when compared to GE and GE-M scaffolds on day 1. GE-M 
scaffolds also attached more cells than the GE control providing mineralized GE scaffolds 
with an advantage. MTS cell proliferation results indicated that PHCE scaffolds increased 
cell proliferation after 4 and 7 days when compared to GE controls. It is also evident that 
the addition of a mineral coating to GE scaffolds increases cell proliferation at day 4. 
Analysis of MG-63 protein/cytokine secretion suggests that the cells are responding in a 
bone regenerative fashion on all scaffolds, as evidence of osteocalcin secretion. Little to no 
secretion of osteopontin, IL-1β, and TNF-α proves that the scaffolds are not influencing 
the cells to respond in a resorptive manner. For compressive mechanical testing, cells 
continuously remodeled the scaffolds making it is difficult to extract relationships. Some 
key observations for peak load included at one point (day 14) for PHCE and PHCE-M 
scaffolds, cells remodeled the scaffold which increased peak load. Also the GE-M 
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cellularized scaffolds recorded higher peak load values on days 14 and 21. Analysis of 
compressive modulus suggests that for non-mineralized cellular scaffolds (GE and PHCE), 
only significant increases were recorded on day 21. This data suggests that after 21 days, 
the cells are remodeling non-mineralized scaffolds in a manner that ultimately increases 
the scaffold’s stiffness. Generally, the Young’s modulus for compression of mineralized 
scaffolds remained unaffected as a result of the addition of cells. The comprehensive 
results from this study support the notion of mineralizing GE scaffolds to increase cellular 
attachment, infiltration, and bone regenerative protein/cytokine secretion. Cellularized 
PHCE and PHCE-M scaffolds also report similar advantages as GE-M scaffolds, but also 
have compressive mechanical modulus values in the range of native tissues present in the 
early stages of bone healing. Visually, after complete mechanical compression, cellularized 
PHCE and PHCE-M scaffolds performed superior as they remained intact suggesting their 
ability to withstand increased mechanical stress.   
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6. CONCLUSION AND FUTURE STUDIES   
  
To certain extents, the human body has the unique ability to repair itself following 
injury. However, if the injuries exceed a critical size or level of damage, then surgical 
intervention is required to enhance the body’s own reparative process. The field of tissue 
engineering focuses on developing viable substitutes that are able to repair and regenerate 
the functions of damaged tissue. Specifically, bone tissue engineering can provide 
improved bone grafting materials such as a porous, biocompatible, and biodegradable 
scaffold capable of sustained release of growth factors and cytokines to promote 
osteogenesis. Scaffolds such as these can improve the quality of life in patients by 
eliminating common drawbacks of current bone grafting procedures and materials such as 
the need for a secondary surgery for an autograft and the lack of biodegradability with 
ceramic/metal implants. 
Lyophilizing a frozen gelatin solution is one fabrication method that has been used 
to create bone graft analogues, as it consistently produces hygroscopic porous scaffolds of 
any size with the ability to swell and fill any void space or defect. These freeze-dried 
scaffolds also have tailorable degradation rates and the ability to incorporate several factors 
(proteins, growth factors, nanofillers, etc.). HA is a popular biocompatible nanofiller which 
is incorporated within lyophilized sponges and several other bone tissue engineering 
scaffolds. This study investigates the very first attempts of incorporating PRGF and/or CW 
within lyophilized sponges. The present study was dedicated to developing a scaffold 
intended for bone repair. This biodegradable scaffold was specifically designed to mimic 
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the biological, biochemical, and mechanical microenvironment of the early stages of bone 
healing. In the present study, the first goal was to fabricate a cross-linked three-
dimensional porous lyophilized gelatin sponge enhanced with PRGF, HA, and/or CW. We 
then investigated the different ways in which these enhancements altered the biological, 
mechanical, and regenerative characteristics with the intention of creating a bioresorbable 
graft that would have the ability to become completely remodeled into functioning new 
bone. Scaffolds were preliminarily evaluated to determine the advantages of various 
compositions and cross-linking methods of composite lyophilized gelatin sponges. This 
study illustrated that a lyophilized gelatin sponge, incorporated with PRGF, HA, and CW, 
demonstrated osteogenic potential when cultured with an MG-63 osteoblast-like cell line. 
These scaffolds, further modified through EDC cross-linking during gelation, exhibited 
controlled protein release (degradation), increased cellular attachment/infiltration, 
remained intact after 90 days in culture, and promoted the secretion of cell-created bone 
matrix. This tailorable rate of degradation is critical in a bone repair scaffold, where 
scaffold breakdown needs to match the ingrowth of vasculature and new bony matrix to 
prevent catastrophic failure. While the overall comparison of scaffolds did not clearly 
predict which combinations of PRGF, HA, and CW would induce optimal bone 
regeneration, it does give some insight to the advantages of the addition of growth factors 
and nanofillers to lyophilized gelatin sponges. The lyophilized sponges containing PRGF, 
HA, CW, and cross-linked during gelation (PHCE) performed well in the preliminary 
evaluations and were further investigated.   
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In an effort to further enhance the bioactivity and biocompatibility of cross-linked 
during gelation gelatin (GE) and PHCE scaffolds, SBF treatment was used to create a 
bone-like mineral surface on the scaffolds. For PHCE scaffolds, this is similar to the dual 
mineralization strategy used in our lab where a scaffold is fabricated with HA and 
subsequently mineralized with SBF. GE scaffolds nucleated minerals in more of a sparse 
aggregate manner while PHCE scaffolds showed more uniform biomimetic mineralization 
across the surface.  GE and PHCE scaffolds were also evaluated for the ability to swell and 
both demonstrated the ability to swell 50% of their original volume upon hydration. In 
addition to analyzing scaffold characteristics, a growth factor profile of PRGF, PRP, and 
PPP was obtained to identify which factors were present and at what concentrations. The 
highest concentrations of growth factors detected in PRGF and PRP were HGF and VEGF-
A. The growth factor profile of PPP (1:10) more closely resembled that of PRGF (1 and 
0.1 mg/mL), both highly diluted solutions. These factors all have been shown to increase 
the formation of bone either through increased vascularization or bone mineral density and 
support their incorporation within scaffolds. This study also showed that PHCE-M 
scaffolds degraded faster and released 30% of its original protein content over 21 days. 
Although PHCE-M scaffolds degraded the fastest, no PRGF growth factors were 
detectable after analyzing scaffold release contents. However, multiplexer analysis did 
reveal the successful incorporation of PRGF within uncross-linked PHC sponges. As 
previously mentioned, an important parameter for tissue engineering scaffolding is the 
comparable mechanical properties of the scaffold and the native tissue being regenerated. 
The lower compression moduli values of PHCE and PCHE-M scaffolds are comparable to 
125 
 
moduli values of tissues found in the early stages of bone healing. The creation of these 
enhanced lyophilized sponges proved to have sustainable release, osteoinductive, and 
mechanical properties that could be conducive for bone graft applications; however, the 
bioactivity and cellular response of these materials were not investigated in this study. 
These findings suggest that PHCE and PHCE-M scaffolds have potential for use as early 
bone healing tissue scaffolds and support future in vitro cellularized studies to assess 
cellular responses to the various composite porous sponges. 
Finally, the MG-63 cell response to scaffolds and scaffold response to cells was 
explored. A basic EDC cytotoxicity assay was performed and determined that uncross-
linked EDC in any concentration (from 0.8 – 50 mM) is cytotoxic to MG-63 cells. 
Therefore, since cells on scaffolds survived for up to 90 days (Chapter 3) and 21 days 
(Chapter 5), it can be concluded that there is no residual uncross-linked EDC that will 
negatively affect cell response. In this study, cells were dynamically seeded on floating 
scaffolds in a bioreactor to more appropriately simulate cell recruitment and attachment to 
scaffolds compared to the static cell seeding method. Since individual cells were not 
discernible on the scaffold surface upon SEM examination, it is believed that the dynamic 
cell seeding technique enhanced cell infiltration and potentially cell integration with the 
scaffolds. Both DAPI staining and MTS cell proliferation assay confirmed the presence 
and viability of cells cultured on scaffolds. DAPI imaging showed a noticeable increase in 
initial cell attachment and infiltration of GE-M, PHCE, and PHCE-M scaffolds when 
compared to GE controls. This data supports the mineralization of GE sponges and the 
incorporation of PRGF, HA, and CW within GE scaffolds. The ability to attach cells 
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throughout the entire scaffold at early time points is an attractive quality when considering 
scaffolds for any tissue engineering applications where the cells are able to remodel the 
scaffold as a unit rather than portions at a time. Cell proliferation results indicated that GE-
M and PHCE scaffolds increased cell proliferation after day 1 when compared to GE. For 
PHCE-M scaffolds, cell proliferation results showed a significant decrease in cell number. 
This was a surprising result since DAPI staining confirmed the presence of many cells on 
PHCE-M scaffolds at days 1 and 4. Since MTS measures the mitochondrial activity of 
proliferating cells, it is possible that the cells attached to PHCE-M are no longer in a 
proliferative state. These results propose interesting questions to be answered in future 
studies in which alternative methods for cell counting (such as trypan blue) can be 
explored. Analysis of MG-63 protein/cytokine secretion suggests that the cells are 
responding in a bone regenerative fashion on all scaffolds, as evidence of osteocalcin 
secretion. At early time points (day 1), small amounts of IL-6 secretion was detected. IL-6 
is debated in the literature and appears to have effects both on bone regeneration and 
resorption. Multiplexer analysis also reported little to no secretion of osteopontin, IL-1β, 
and TNF-α, which demonstrates that the scaffolds are not influencing the cells to respond 
in a resorptive manner. Analysis of compressive modulus suggests that after 21 days, the 
cells are remodeling non-mineralized scaffolds in a manner that ultimately increases the 
scaffold’s stiffness. Generally, the Young’s modulus for compression of mineralized 
scaffolds remained unaffected as a result of the addition of cells. The moduli values for 
cellularized scaffolds remained in the low MPa range as found in native tissue involved in 
early bone healing. Upon examination after complete mechanical compression, the gross 
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appearance of cellularized PHCE and PHCE-M scaffolds performed superior as they 
remained intact, suggesting their ability to withstand increased mechanical stress.   
The comprehensive results from this study support the notion of mineralizing GE 
scaffolds to increase cellular attachment, infiltration, and bone regenerative 
protein/cytokine secretion. Cellularized PHCE and PHCE-M scaffolds also report similar 
advantages as GE-M scaffolds, but also have compressive mechanical modulus values in 
the range of native tissues present in the early stages of bone healing. Lyophilized PHCE 
and PHCE-M are bioactive, biocompatible, porous, degradable, osteogenic, and 
mechanically similar to tissues found in early bone healing. These scaffolds satisfy the 
requirements of a bone tissue engineering scaffold and the presented comprehensive results 
support future inflammatory bone healing response and eventually in vivo studies. 
6.1. Future research  
 A couple areas of interest for future direction are analysis of nanofiller particle 
dispersion throughout the scaffold and chemical analysis of the scaffold surface. 
Transmission electron microscopy can be performed on various cross sections of each 
scaffold to visually determine the location and dispersal of the nanofillers (HA and CW) 
within the scaffolds. Ideally, sonication of these particles prior to gelation achieves a 
homogeneous dispersal of HA and CW throughout the scaffold. Very preliminary 
experiments have been performed to analyze the chemical composition of the scaffold 
surface. Energy dispersive x-ray spectroscopy (EDS) was performed on the original GE 
and PHCE scaffolds to determine if the incorporation of the nanofillers (particularly HA) 
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are detected on the surface. Figure 6.1 illustrates the SEM image and corresponding EDS 
analysis for both GE and PHCE scaffolds. EDS was performed in two different areas 
within the sample to ensure homogeneity (only one is reported below). Defined peaks of 
carbon and oxygen were recorded for both scaffolds. This could be attributed to the carbon 
coating used to prepare the samples and the fact that the primary material of these scaffolds 
is gelatin (chemical structure of carbon, hydrogen, oxygen, and nitrogen). For the GE EDS 
spectrum, chlorine and sulfur were also detected. This is thought to be the result of the 
presence of residual ions left behind by the DI water (which when filtered, did not entirely 
remove ions present in the standard tap water). The more defined chlorine peak is more 
likely a result from the detection of EDC cross-linking. EDC has a chemical composition 
of carbon, hydrogen, nitrogen, and chlorine elements. In either instance, the GE EDS 
spectrum was used as a control. Upon PHCE EDS analysis, elemental peaks of calcium, 
phosphate, and sodium (smaller peak) are detected. This suggests that HA is successfully 
incorporated within the scaffold and present to some degree on its surface.  EDS was also 
performed on mineralized samples, however the results were not consistent enough to draw 
any conclusions. The chemical analysis of a mineralized scaffold is of interest for future 
studies.  
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Figure 6.1 - SEM and EDS analysis of GE (A and B) and PHCE (C and D) scaffolds. 
 
 In addition to surface characterization, degradation will be more appropriately 
assessed through a variety of experiments analyzing specific components. First the release 
of gelatin, PRGF, and Ca-P, will be studied individually to determine how the scaffold is 
degrading and which contents are being released. The presence of calcium on the scaffold 
surface can be quantified over time which will provide insight to the scaffold mineral 
content as components are being released. The combination of these experiments provides 
a more comprehensive analysis of scaffold degradation. Other future experiments include 
analysis of porosity, detection of RANKL for a more general understanding of osteoblast 
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bone remodeling signals, and the potential application of these scaffolds for cartilage tissue 
engineering (since mechanical properties are within the range of native cartilage). 
To more appropriately assess each scaffold’s ability to promote bone healing, the 
response of inflammatory (monocytes/macrophages) and primary (osteoprogenitor) cells 
will need to be explored. As previously mentioned, bone healing consists of three main 
stages: inflammatory, repair, and remodeling. One of the main interests of this study is to 
determine the scaffold’s ability to influence inflammatory cell behavior (cells present in 
the first stages of bone healing). This includes the attraction and differentiation of 
monocytes into macrophages, the subsequent polarization of macrophages to a pro-
inflammatory (M1) or pro-regenerative (M2) state, the characterization of growth factors 
released by macrophages, and the osteoinductive capability of these growth factors with 
respect to MSC differentiation into osteoblasts. It is known that macrophages must 
transition to the M2 phenotype to facilitate proper tissue remodeling after disinfecting and 
debriding a site of injury [150]. Clinically, scaffolds can be fabricated with a quick 
turnaround from a patient’s PRP blood draw to fabrication of the sponges. The hypothesis 
of this future study is that the PHCE sponge will serve as a bioactive structure to facilitate 
sustained delivery and presence of PRGF, differentiation of monocytes into pro-
regenerative (M2) macrophages, and macrophage secretion of osteoinductive growth 
factors which will result in the differentiation of osteoprogenitor cells (such as 
mesenchymal stem cells) into osteoblasts. The end goal of this future work will be to 
create an implantable bone healing microenvironment mimicking analogue containing the 
necessary cues to integrate properly with a patient’s own bone which has been injured. 
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tenure at VCU, Isaac was involved with several campus and community organizations. 
Some of which included: Student Today Alumni Tomorrow (President), Hispanic College 
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Fund University Chapter at VCU (Co-Founder and Alumni Advisor), the American 
Society of Artificial Internal Organs: for young innovators (Co-Founder and Vice 
President), the Alpha Psi Chapter of La Unidad Latina, Lambda Upsilon Lambda 
Fraternity, Inc. ((alumni advisor), VCU Latino Alumni Council (Co-Founder and Board 
Member), 2018 School of Engineering Strategic Planning Committee, 2012 HCF Greater 
Washington Hispanic Youth Institute (Assistant Director), 2012 VALHEN Hispanic 
College Institute (Assistant Director), and more. As a result of his dedication to the VCU 
and Richmond community, VCU’s President, Dr. Michael Rao, awarded Isaac the Student 
Award for the Presidential Awards for Community and Multicultural Enrichment 
(PACME) in 2012. Within the PACME awards, Isaac was also awarded the capstone 
Riese-Melton Award (highest honor). Isaac has also won other University-wide Leadership 
and Service awards, VCU Alumni Association alumni service recognition, as well as the 
2009-2010 Who’s Who Among Students in American Universities and Colleges 
recognition at VCU. Isaac will continue his research in bone tissue engineering through a 
2-year postdoctoral fellowship starting in the summer of 2013. 
  
